azacitidine has been researched along with Neoplasms in 212 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 31 (14.62) | 18.7374 |
| 1990's | 17 (8.02) | 18.2507 |
| 2000's | 78 (36.79) | 29.6817 |
| 2010's | 75 (35.38) | 24.3611 |
| 2020's | 11 (5.19) | 2.80 |
| Authors | Studies |
|---|---|
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Arimondo, PB; Erdmann, A; Fahy, J; Halby, L | 1 |
| Arellano, ML; Boggon, TJ; Brat, DJ; Chen, GZ; Chen, J; Chen, PR; DeBerardinis, RJ; Elf, S; Fan, J; Gu, TL; He, C; Hitosugi, T; Hurwitz, SJ; Ji, Q; Jiang, L; Kang, HB; Kang, S; Khoury, HJ; Khuri, FR; Lee, BH; Lei, Q; Li, Y; Lin, R; Lonial, S; Mao, H; Mitsche, M; Seo, JH; Shan, C; Sudderth, J; Tucker, M; Wang, D; Wu, S; Xie, J; Ye, K; Zhang, L; Zhang, S; Zhou, L | 1 |
| Beauvais, D; Chauvet, P; Coiteux, V; Drumez, E; Duhamel, A; Magro, L; Quesnel, B; Srour, M; Wattebled, KJ; Yakoub-Agha, I | 1 |
| Ding, K; Duan, L; Fu, R; Guo, Y; Liu, Z; Shen, H | 1 |
| Berthon, C; Carpentier, B; Chauvet, P; Goursaud, L; Lionne-Huyghe, P; Nibourel, O; Quesnel, B; Wemeau, M | 1 |
| Fukuda-Kurahashi, Y; Hattori, N; Kamachi, K; Kawaguchi, A; Kimura, S; Kurahashi, Y; Nakamura, H; Sueoka, E; Ureshino, H; Ushijima, T; Watanabe, T; Yamamoto, Y; Yamashita, S; Yoshida-Sakai, N | 1 |
| Altrock, E; Costina, V; Darwich, A; Fabarius, A; Flach, J; Hofmann, WK; Jäger, E; Jann, JC; Jawhar, A; Jawhar, M; Kuzina, M; Levkin, PA; Marx, A; Metzgeroth, G; Neumaier, M; Nolte, F; Nowak, D; Nowak, V; Obländer, J; Palme, I; Rapp, F; Riabov, V; Schmitt, N; Sens-Albert, C; Sperk, E; Steiner, L; Streuer, A; Weimer, N; Weis, CA; Wolf, J; Wuchter, P; Xu, Q | 1 |
| Bernard, E; Chiba, S; Creignou, M; Handa, H; Hellström-Lindberg, E; Hiramoto, N; Imada, K; Ishikawa, T; Kakiuchi, N; Kasahara, S; Kiguchi, T; Kusakabe, M; Makishima, H; Miyano, S; Miyazaki, Y; Nakagawa, M; Nakamura, N; Nannya, Y; Naoe, T; Ogawa, S; Ohtake, S; Ohyashiki, K; Papaemanuil, E; Sato, S; Shibata, Y; Shiozawa, Y; Shiraishi, Y; Taguchi, M; Takaori-Kondo, A; Takeda, J; Tanaka, H; Tobiasson, M; Tsurumi, H; Usuki, K; Watanabe, M; Yoshida, K; Zhao, L | 1 |
| Bendell, J; Blagden, SP; Brana, I; Chiorean, EG; Fakih, M; Geschwindt, R; Goff, LW; Kristeleit, R; Kurzrock, R; Luke, JJ; Naing, A; O'Hayer, K; Schneider, C; Smith, M; Zhou, F | 1 |
| Battafarano, RJ; Baylin, SB; Brahmer, JR; Brock, MV; Broderick, SR; Bush, EL; Cai, Y; Cattaneo, SM; Cui, Y; Day, CP; Easwaran, H; Forde, PM; Housseau, F; Huang, P; Hulbert, A; Jiao, X; Juergens, RA; Kim, K; Kim, YJ; Kong, X; Lee, B; Li, H; Li, S; Lu, Z; Margolick, JB; Mei, Y; Nelkin, BD; Pardoll, DM; Riemer, JB; Rodgers, K; Rudin, CM; Shen, L; Tao, Y; Topper, MJ; Vaz, M; Wang, KK; Wang, Y; Wrangle, J; Xia, L; Xie, W; Yang, SC; Yen, RC; Zahnow, CA; Zhang, B; Zhang, H; Zhang, W; Zou, J | 1 |
| Chandran, NS; Koh, XQ; Ooi, XT; Sun, Y; Tan, CL | 1 |
| Amigo, M; Antón, AI; Beltrán, V; Calabria, I; Carrillo-Tornel, S; Chen-Liang, TH; Cifuentes, R; Hurtado López, AM; Jerez, A; Muiña, B; Muro, M; Navarro-Villamor, N; Panadero, J; Salido, EJ; Teruel, R; Vicente, V; Zurdo, M | 1 |
| Fandy, TE; Uddin, MG | 1 |
| Hu, L; Li, G; Shen, Q; Yao, Y; Zhang, X; Zhou, J | 1 |
| Allen, B; Masternak, MM; Muller, MT; Pezone, A; Porcellini, A | 1 |
| Bai, F; Krishnadas, DK; Lucas, KG; Sundaram, K; Wang, Y | 1 |
| Chen, M; Dong, L; Feng, K; Han, W; Jia, H; Li, X; Liu, L; Liu, Y; Mei, Q; Nie, J; Shi, L; Zhang, Y | 1 |
| Chen, JK; Ding, HF; Dong, Z; Fan, G; Guo, C; Huang, S; Pei, L; Shi, H; Wei, Q; Xiao, X | 1 |
| Arany, I; Dixit, M; Faisal, A; Hall, S | 1 |
| Kaul, SC; Putri, JF; Sakamoto, K; Wadhwa, R; Widodo, N | 1 |
| Abdollahi, M; Rahmani, S | 1 |
| Alqinyah, M; Hooks, SB | 1 |
| Gao, R; Kalra, RS; Kaul, SC; Kaul, Z; Li, L; Wadhwa, R; Wang, J; Yu, Y; Zhang, Z | 1 |
| Beijnen, JH; Lucas, L; Oganesian, A; Roosendaal, J; Rosing, H; Schellens, JHM | 1 |
| Balgkouranidou, I; Chatzaki, E; Kakolyris, S; Karaglani, M; Kolios, G; Panagopoulou, M; Pantazi, C | 1 |
| Bartek, J; Dzijak, R; Hodny, Z; Hubackova, S; Imrichova, T; Kyjacova, L; Moudra, A; Pribyl, M; Rob, L; Salovska, B; Strnad, H; Svec, J; Tambor, V; Vaclavikova, R; Vodicka, P | 1 |
| Ahuja, N; Anders, NM; Azad, N; Downs, M; Durham, JN; Gaillard, SL; Reiss, KA; Rudek, MA; Sartorius-Mergenthaler, S; Sharma, A; Zahurak, M | 1 |
| Hattori, N; Iida, N; Kimura, K; Kono, Y; Nakata, Y; Sako, M; Takeshima, H; Ushijima, T | 1 |
| Wolfson, W | 1 |
| Held, G; Kaddu-Mulindwa, D; Kubuschok, B; Neumann, F; Pfreundschuh, M; Preuss, KD; Roemer, K; Widmann, T; Zwick, C | 1 |
| Bustinza-Linares, E; Falchook, GS; Fu, S; Hong, DS; Hu, W; Kurzrock, R; Moulder, S; Naing, A; Parkhurst, KL; Sood, AK; Wheler, JJ | 1 |
| Berger, A; Bitzer, M; Essmann, F; Fulda, S; Häcker, S; Johnstone, RW; Lauer, UM; Nuebling, T; Salih, HR; Schenk, M; Schulze-Osthoff, K; Sipos, B; Venturelli, S; Waibel, M; Weiland, T | 1 |
| Fu, LJ; Lou, XY; Qu, J; Qu, Q; Wu, LX; Zhan, M; Zhang, YW; Zhou, HH | 1 |
| Ewing, R; Scott, A; Song, J; Wang, Z | 1 |
| Ahuja, N; Azad, NS; Baylin, SB; Chiappinelli, KB; Connolly, RM; Davidson, N; Easwaran, H; Guzzetta, AA; Jones, PA; Li, H; Luo, J; Pardoll, DM; Slamon, DJ; Stearns, V; Topper, MJ; Vatapalli, R; Yen, RW; Zahnow, CA | 1 |
| Beach, CL; Gabrail, NY; Goel, S; Kelly, K; Laille, E; Liu, L; Mita, AC; Songer, S | 1 |
| Fanger, G; Knox, S; Oronsky, B; Oronsky, N; Scicinski, J | 1 |
| Chen, M; Fan, H; Feng, K; Fu, X; Guo, B; Han, W; Liu, Y; Lu, X; Nie, J; Shi, F; Wang, X; Wang, Y; Zhang, W; Zhang, Y; Zhu, H | 1 |
| Han, W; Li, X; Liu, L; Nie, J | 1 |
| Huang, Y; Rao, A | 1 |
| Boureau, L; Cheishvili, D; Szyf, M | 1 |
| Henikoff, S; Kasinathan, S | 1 |
| Hattori, N; Takeshima, H; Ushijima, T; Wakabayashi, M; Yamashita, S | 1 |
| Fu, X; Han, W; Li, X; Mei, Q; Nie, J | 1 |
| Azab, M; Coral, S; Covre, A; Di Giacomo, AM; Maio, M; Taverna, P | 1 |
| Anders, NM; Azad, NS; He, P; Rudek, MA; Wanjiku, TM | 1 |
| Ferruccio, LF; Incekol, D; Lee, R; Murray, C; Ng, P; Paisley, E; Yee, KW | 1 |
| Diederich, M; Schnekenburger, M | 1 |
| Dear, AE | 1 |
| Gao, D; Guo, M; Herman, JG | 1 |
| Chen, M; Han, W; Li, X; Liu, C; Nie, J; Zhang, Y | 1 |
| Arnold, RD; Cummings, BS; Glenn, TC; Kolli, RT; Moore, M; Scholpa, NE | 1 |
| Andresini, O; Battistelli, C; Carbone, M; Ciotti, A; Maione, R; Rossi, MN | 1 |
| Levine, AJ | 1 |
| Annereau, M; Auger, N; Bermudez, E; Chahine, C; Danu, A; de Botton, S; Desmaris, RP; El Halabi, L; Ghez, D; Lazarovici, J; Leary, A; Lemare, F; Micol, JB; Pistilli, B; Saada, V; Solary, E; Willekens, C | 1 |
| Issa, JJ; Kropf, P; Sato, T | 1 |
| Butter, R; Linnekamp, JF; Medema, JP; Spijker, R; van Laarhoven, HWM | 1 |
| Chang, CK; Guo, J; Li, X; Song, LL; Wu, D; Wu, LY; Xiao, C; Xu, F; Zhao, YS | 1 |
| Asano, Y; Nakajima, W; Oda-Sato, E; Takeshita, T; Tanaka, N; Uehara, I; Yagi, S | 1 |
| Shvachko, LP | 2 |
| Alexander, S; Braiteh, F; Garcia-Manero, G; Hong, D; Johnson, MM; Kurzrock, R; Silva, Lde P; Soriano, AO; Wolff, J; Yang, H | 1 |
| Bigl, M; Eschrich, K; Horn, LC; Jandrig, B | 1 |
| Garcia-Manero, G; Jain, N; Rossi, A | 1 |
| Aghai, Z; Blokland, E; Bruijn, JA; Goulmy, E; Halfwerk, H; Hambach, L; Ling, KW; Pool, J; Tanke, HJ; van Boven, H; Wieles, B | 1 |
| Chihara, Y; Chuang, JC; Egger, G; Friedman, JM; Liang, G; Saito, Y | 1 |
| Goto, M; Higashi, M; Nishida, Y; Nomoto, M; Tsutsumida, H; Yamada, N; Yonezawa, S | 1 |
| Issa, JP | 3 |
| Aparicio, A; Barske, L; Bollati, V; Groshen, S; Horne, E; Issa, JP; Jones, P; North, B; Tannir, N; Wang, X; Weisenberger, D; Yang, A; Yoo, C | 1 |
| Guo, Z; Gupta, S; Hong, D; Issa, JP; Jelinek, J; Kurzrock, R; Nunez, MI; Oki, Y; Stewart, DJ; Wistuba, II | 1 |
| Issa, JP; Kantarjian, HM | 3 |
| Ambinder, RF; Baker, SD; Carducci, MA; Donehower, RC; Gilbert, J; Gore, S; Herman, JG; Jiemjit, A; Lin, J; Rudek, MA; Zhao, M; Zwiebel, JA | 1 |
| Li, BH; Li, F; Li, PD; Liu, XH; Xu, SB; Yuan, J; Yuan, Q; Zhang, WJ; Zhang, Y | 1 |
| Blagitko-Dorfs, N; Daskalakis, M; Hackanson, B | 1 |
| Ding, J; Liang, Q; Xu, R; Xu, Z; Zheng, S | 1 |
| An, SX; Chen, XL; Cui, W; Li, BL; Lu, YY; Mi, XY; Song, M; Wang, EH; Wang, LH; Wen, YY; Xu, M; Zhao, J | 1 |
| Eckschlager, T; Hrabeta, J; Hrebackova, J | 1 |
| Bearss, DJ; Chuang, JC; Jones, PA; Qiu, X; Redkar, S; Vankayalapati, H; Vollmer, D; Warner, SL; Yoo, CB | 1 |
| Brueckner, B; Fichtner, I; Hals, PA; Lyko, F; Markelova, MR; Rius, M; Sandvold, ML | 1 |
| Adamson, PC; Blaney, SM; Diller, L; Finkelstein, D; George, RE; Ingle, AM; Krailo, M; Lahti, JM; Neuberg, D; Reid, JM; Zhu, K | 1 |
| Fujimoto, J; Hong, WK; Kong, M; Lee, JJ; Lotan, R | 1 |
| Bazhin, AV; De Smet, C; Golovastova, MO; Philippov, PP; Schmidt, J | 1 |
| Farkas, DL; Gertych, A; Tajbakhsh, J | 1 |
| Han, H; Jones, PA; Lay, F; Yang, X | 1 |
| Esteller, M; Kulis, M | 1 |
| Catto, JW; Choudhry, H | 1 |
| Moss, T | 1 |
| Chen, EX; Egorin, MJ; Espinoza-Delgado, I; Hirte, HW; Holleran, JL; Hotte, SJ; Laughlin, A; McGill, S; Moretto, P; Oza, AM; Siu, LL; Stathis, A; Stayner, LA; Wang, L; Webster, S; Zhang, WJ | 1 |
| Adams, S; Anderson, J; Basu, BP; Dalgleish, A; Hasan, F; Himoudi, N; Poon, E; Wallace, R; Williams, O; Wilson, N; Xue, SA; Yan, M | 1 |
| Gronemeyer, H; Hahn, WC; Kedinger, V; Khanwalkar, H; Kotova, I; Lund, P; Voltz, E | 1 |
| Kumar, A; Prasada, KS; Rai, PS; Rao, BS; Satyamoorthy, K; Upadhya, R | 1 |
| Bauman, J; Belinsky, S; Fekrazad, M; Jones, D; Lee, SJ; Muller, C; Ravindranathan, M; Rutledge, T; Verschraegen, C | 1 |
| Chau, S; Foulks, JM; Hendrickson, TF; Ho, KK; Kanner, SB; McCullar, MV; Nix, RN; Parnell, KM; Saunders, M; Swierczek, K; Wright, K | 1 |
| Cowan, LA; Talwar, S; Yang, AS | 1 |
| Cao, S; Liao, DJ; Lin, X; Song, X; Sun, Y; Wang, Z; Wu, S; Yang, M | 1 |
| Krečmerová, M; Otmar, M | 1 |
| Bock, C; Do, H; Dobrovic, A; Mikeska, T | 1 |
| Colizzi, F; Coral, S; Covre, A; Danielli, R; Fratta, E; Maio, M; Nicolay, HJ; Parisi, G; Sigalotti, L; Taverna, P | 1 |
| Arimondo, PB; Ceccaldi, A; Champion, C; Daunay, A; Fourrière, L; Guieysse-Peugeot, AL; Lacomme, S; Moison, C; Senamaud-Beaufort, C; Tost, J | 1 |
| Christman, JK | 1 |
| Jones, DA; Karpf, AR | 1 |
| Chaudhary, PM; Gazdar, AF; Harada, K; Hay, RJ; Maitra, A; Mastrangelo, D; Matta, H; Miyajima, K; Reddy, JL; Shivapurkar, N; Timmons, CF; Tomlinson, GE; Toyooka, S | 1 |
| Benhattar, J; Braunschweig, R; Coindre, JM; Guilleret, I; Guillou, L; Yan, P | 1 |
| Avila, S; Esteller, M; Fraga, MF; Guo, M; Herman, JG; Paz, MF; Pollan, M | 1 |
| Durkin, ME; Popescu, NC; Yuan, BZ | 1 |
| Aparicio, A; Baker, SD; Eads, CA; Laird, PW; Leong, LA; Newman, EM; Synold, TW; Weber, JS; Zhao, M | 1 |
| Boon, T; De Smet, C; Loriot, A | 1 |
| SORM, F; VESELY, J | 1 |
| Benhattar, J; Guilleret, I | 1 |
| Longo, M; Nelson, PS; Schuster, JM | 1 |
| Estecio, MR; Garcia-Manero, G; Issa, JP; Kantarjian, HM; Yang, AS | 1 |
| Honoki, K; Mii, Y; Mori, T; Takakura, Y; Tsujiuchi, T; Tsutsumi, M; Yoshitani, K | 1 |
| Miyamoto, K; Ushijima, T | 1 |
| Dowell, JE; Minna, JD | 1 |
| Chen, XQ; Garcia-Manero, G; Higuchi, E; Issa, JP; Kondo, Y; Lotan, R; Youssef, EM | 1 |
| Assaly, M; Benz, A; Cerato, C; Desmond, JC; Greloz, V; Hermeking, H; Herrmann, F; Koeffler, HP; Lodygin, D; Mhawech, P; Schwaller, J | 1 |
| Brambilla, E; Czerniak, B; Fujisawa, T; Gazdar, AF; Mastrangelo, D; Miyajima, K; Pass, HI; Sathyanarayana, UG; Shigematsu, H; Shimizu, N; Shivapurkar, N; Suzuki, M; Takahashi, T; Tomlinson, GE; Toyooka, S | 1 |
| Bisht, KS; Bradbury, CM; Brandenburg, SA; Chuang, EY; Cook, J; Cui, H; Feinberg, AP; Gius, D; Ho, AS; Hu, Y; Mattson, D; Mitchell, JB; Munson, PJ; Smart, DK; Sun, L; Young, L; Zhao, S | 1 |
| Cheng, JC; Jones, PA; Yoo, CB | 1 |
| Tuma, RS | 1 |
| Bilchik, AJ; Fujimoto, A; Hoon, DS; Shinozaki, M; Takeuchi, H; Umetani, N | 1 |
| Arthur, C | 1 |
| Boucher, K; Busby, L; Cassidy, P; Fitzpatrick, F; Jones, DA; Karpf, AR; Leachman, SA; Porter-Gill, P; Samlowski, WE; Wade, M; Wheeler, R | 1 |
| Ehrlich, M | 1 |
| Awwad, RT; Bisht, KS; Bradbury, CM; Gius, D; Ho, AS; Huang, L; Nguyen, P; Smart, DD; Sun, L | 1 |
| Libermann, TA; Zerbini, LF | 1 |
| Ambinder, R; Gao, Z; Hsieh, WS; Liao, SK; Murray, P; Srivastava, G; Tao, Q; Ying, J | 1 |
| Raut, CG; Somasundaram, K; Wajapeyee, N | 1 |
| de Vos, D | 1 |
| Momparler, RL | 1 |
| Murgo, AJ | 1 |
| Rosenfeld, CS | 1 |
| Almstedt, M; Claus, R; Lübbert, M | 1 |
| Baylin, SB | 1 |
| Chen, GA; Guo, ZS; Hong, JA; Irvine, KR; Liu, Y; Nguyen, DM; Restifo, NP; Schrump, DS; Spiess, PJ; Wunderlich, JR; Zeng, G | 1 |
| Auer, H; Brena, RM; Byrd, JC; Hackanson, B; Kornacker, K; Plass, C; Raval, A | 1 |
| Berenguer, J; Borczuk, AC; Hei, TK; Powell, CA; Shao, G; Zhao, Y | 1 |
| Pantel, K; Schwarzenbach, H; Wischnewski, F | 1 |
| Lee, KD; Lin, CT; Lin, WH; Tzeng, PY | 1 |
| Diamandis, EP; Pampalakis, G; Sotiropoulou, G | 1 |
| Albert, SH; Liao, D; Liu, J; Niu, Y; Robertson, KD; Santiago, A; Zhao, LY | 1 |
| Aoki, E; Issa, JP; Oki, Y | 1 |
| Mack, GS | 1 |
| Aparicio, AM; Egger, G; Escobar, SG; Jones, PA | 1 |
| Chung, DH; Jeon, YK; Jeong, SJ; Kang, HC; Kim, IJ; Lee, CW; Park, HY; Shin, HJ | 1 |
| Aubert, JP; Desseyn, JL; Perrais, M; Pigny, P; Van Seuningen, I; Vincent, A | 1 |
| Habano, W; Jiao, YF; Nakamura, S; Sugai, T | 1 |
| Issa, JP; Plimack, ER; Stewart, DJ | 1 |
| Appleton, K; Barrett, S; Bellenger, K; Brown, R; Jadayel, D; Judson, I; Kaye, SB; Lee, C; Mackay, HJ; Mackay, L; McCormick, C; Plumb, JA; Reade, S; Schätzlein, A; Setanoians, A; Strathdee, G; Tang, A; Twelves, C | 1 |
| Brown, KD; Palii, SS; Robertson, KD; Sankpal, UT; Van Emburgh, BO | 1 |
| Arrouss, I; Billot, K; Cario-Andre, M; Duhamel, M; Navarro, P; Rebollo, A | 1 |
| Awwad, R; Bisht, KS; Bradbury, CM; Gius, D; Huang, L; Kaushal, A; Markovina, S; Mishra, MV; Muldoon-Jacobs, K; Nguyen, P; Pennington, JD; Sun, L | 1 |
| Lyko, F; Stresemann, C | 1 |
| Kessel, D; Khilanani, P; Lomen, PL | 1 |
| Ellims, PH | 1 |
| Jones, PA; Riggs, AD | 1 |
| Chabner, BA; Clendeninn, NJ; Curt, GA | 1 |
| Hoffman, RM | 1 |
| Carlow, DA; Elliott, BE; Frost, P; Kerbel, RS; Liteplo, R | 1 |
| Herlyn, M; Johnson, B; Lassam, N; Rosenberg, SA; Salgaller, M; Samid, D; Treisman, J; Weber, J | 1 |
| Bernstein, ML; Devine, S; Dubowy, R; Grier, H; Kung, F; Land, V; Murphy, S; Whitehead, VM | 1 |
| Baylin, SB; Burger, PC; Gabrielson, E; Herman, JG; Lee, DJ; Mao, L; Merlo, A; Sidransky, D | 1 |
| Boon, T; Brasseur, F; De Backer, O; De Smet, C; Faraoni, I; Lurquin, C | 1 |
| Bird, AP | 1 |
| Nyce, JW | 1 |
| Bender, CM; Jones, PA; Pao, MM | 1 |
| Boon, T; Brasseur, F; Brasseur, R; De Plaen, E; De Smet, C; Lurquin, C; Martelange, V; Monaco, AP; Muscatelli, F | 1 |
| Issa, JP; Lengauer, C | 1 |
| Drummond, J; Kasturi, L; Li, GM; Lutterbaugh, JD; Ma, AH; Markowitz, SD; Modrich, PL; Olechnowicz, J; Periyasamy, S; Sedwick, WD; Veigl, ML | 1 |
| Ames, MM; Erlichman, C; Fitch, TR; Goldberg, RM; Kuffel, MJ; Reid, JM; Rubin, J; Sloan, JA | 1 |
| Bachman, KE; Baylin, SB; Cameron, EE; Herman, JG; Myöhänen, S | 1 |
| Arden, KC; Boon, T; Boretti, M; Brasseur, F; Chomez, P; Czekay, S; De Backer, O; De Plaen, E; De Smet, C; Van den Eynde, B; van der Bruggen, P; Vantomme, V; Viars, CS | 1 |
| Jones, PA; Robertson, KD | 1 |
| Bovenzi, V; Momparler, RL | 1 |
| Altomonte, M; Cattarossi, I; Ciullo, M; Coral, S; Gasparollo, A; Guardiola, J; Maio, M; Prisco, A; Sigalotti, L | 1 |
| Carling, T; Du, Y; Fang, W; Huang, S; Piao, Z; Sheu, JC | 1 |
| Hirohashi, S; Kanai, Y; Nakanishi, Y; Saito, Y; Sakamoto, M; Ushijima, S | 1 |
| Aparicio, A; Weber, JS | 1 |
| Chabner, BA; Coleman, CN; Johns, DG; Myers, CE | 1 |
| Kashmin, R; Maruyama, Y; Meeker, WR; Moses, B; Vider, M | 1 |
| Baig, M; Colsky, J; Shnider, BI | 1 |
| Cohen, FB; Custodio, MC; Decter, JA; Lippman, AJ | 1 |
| Carter, SK; Slavik, M | 2 |
| Greenberg, N; Hurtubise, PE; Schumm, DE; Webb, TE | 1 |
| Chabner, BA; Myers, CE; Oliverio, VT | 1 |
| Slavik, M; von Hoff, DD | 1 |
| Amato, R; Ho, D; Krakoff, IH; Raber, M; Schmidt, S | 1 |
| Ben-Baruch, N; Cowan, KH; Fine, R; Ford, H; Kelley, JA; Surbone, A; Thomas, RV | 1 |
| Alberti, D; Arzoomanian, RZ; Bailey, H; Bruggink, J; Tombes, MB; Tutsch, KD; Wilding, G | 1 |
| Brown, TD; Burris, HA; Havlin, KA; O'Rourke, TJ; Rodriguez, GI; Wall, JG; Weiss, GR | 1 |
| Batist, G; Collins, JM; Curt, GA; Fine, RL; Huguenin, PN; Jenkins, J; Kelley, JA; Roth, JS | 1 |
| Kerr, SJ | 1 |
| Jones, PA | 2 |
| Moriconi, WJ; Slavik, M; Taylor, S | 1 |
| Frost, P; Kerbel, RS; Liteplo, R | 1 |
| Gall, HE; Leyva, A; O'Brien, AM; Pinedo, HM; van Groeningen, CJ | 1 |
| Abele, R; Bruntsch, U; Clavel, M; Dodion, P; Gundersen, S; Pinedo, HM; Renard, J; Smyth, J; van Glabbeke, M | 1 |
| Pierce, GB; Speers, WC | 1 |
| Balis, FM; Ettinger, LJ; Ford, H; Gillespie, A; Heideman, RL; Packer, RJ; Poplack, DG; Reaman, GH; Sato, J; Tan, C | 1 |
| Durr, FE; Lindh, D; Wallace, RE | 1 |
| Chandler, LA; Jones, PA | 1 |
| Bellet, RE; Custer, RP; Engstrom, PF; Mastrangelo, MJ | 1 |
| Bruntsch, U; Gallmeier, WM; Osieka, R; Schmidt, CG; Seeber, S | 1 |
| Cihák, A | 1 |
58 review(s) available for azacitidine and Neoplasms
| Article | Year |
|---|---|
Targeting DNA methylation with small molecules: what's next?
Topics: Animals; Antineoplastic Agents; DNA Methylation; DNA Modification Methylases; Drug Discovery; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Humans; Models, Molecular; Molecular Targeted Therapy; Neoplasms; Nucleosides | 2015 |
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Humans; Lipogenesis; Neoplasms; Oxidative Stress; Pentose Phosphate Pathway; Phosphogluconate Dehydrogenase; Protein Serine-Threonine Kinases; Ribulosephosphates; Signal Transduction | 2015 |
Novel treatment opportunities for sulfur mustard-related cancers: genetic and epigenetic perspectives.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cancer Vaccines; Carcinogens; Chemical Warfare Agents; Decitabine; Epigenesis, Genetic; Genetic Therapy; Humans; Hydroxamic Acids; Mustard Gas; Neoplasms; Oncolytic Virotherapy; Vorinostat | 2017 |
Regulating the regulators: Epigenetic, transcriptional, and post-translational regulation of RGS proteins.
Topics: Animals; Azacitidine; Benzodiazepines; Cardiovascular Diseases; Drugs, Investigational; Epigenesis, Genetic; GTP-Binding Proteins; Humans; Hydroxamic Acids; Neoplasms; Neurodegenerative Diseases; Olanzapine; Protein Processing, Post-Translational; RGS Proteins; Signal Transduction; Vorinostat | 2018 |
Regulation of protein stability of DNA methyltransferase 1 by post-translational modifications.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Humans; Hydroxamic Acids; Neoplasms; Protein Processing, Post-Translational; Protein Stability; Vorinostat | 2014 |
Episensitization: therapeutic tumor resensitization by epigenetic agents: a review and reassessment.
Topics: Animals; Antineoplastic Agents; Azacitidine; Azetidines; Benzamides; Decitabine; DNA Modification Methylases; Drug Resistance, Neoplasm; Epigenesis, Genetic; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Neoplasms; Nitro Compounds; Oxidative Stress; Pyridines; Vorinostat | 2014 |
Decitabine, a new star in epigenetic therapy: the clinical application and biological mechanism in solid tumors.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Biomarkers, Tumor; Clinical Trials as Topic; Decitabine; DNA Methylation; Epigenesis, Genetic; Humans; Neoplasms; Prognosis | 2014 |
Connections between TET proteins and aberrant DNA modification in cancer.
Topics: 5-Methylcytosine; Azacitidine; Cytosine; Decitabine; Dioxygenases; DNA Methylation; DNA Modification Methylases; DNA-Binding Proteins; Hematologic Neoplasms; Humans; Isocitrate Dehydrogenase; Mixed Function Oxygenases; Molecular Targeted Therapy; Mutation; Neoplasms; Proto-Oncogene Proteins; Small Molecule Libraries | 2014 |
DNA demethylation and invasive cancer: implications for therapeutics.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Methylation; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasms | 2015 |
Decitabine: a promising epi-immunotherapeutic agent in solid tumors.
Topics: Animals; Azacitidine; Carcinogenesis; Clinical Trials as Topic; Decitabine; DNA Methylation; DNA Modification Methylases; Humans; Immunotherapy; Neoplasms; Tumor Escape | 2015 |
Epigenetics meets immune checkpoints.
Topics: Animals; Antineoplastic Agents; Azacitidine; DNA Methylation; Epigenesis, Genetic; Humans; Immunomodulation; Immunotherapy; Neoplasms | 2015 |
The clinical value of aberrant epigenetic changes of DNA damage repair genes in human cancer.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Biomarkers, Tumor; Carcinogenesis; CpG Islands; Decitabine; DNA Damage; DNA Methylation; DNA Modification Methylases; DNA Repair; DNA Repair Enzymes; Drug Resistance, Neoplasm; Epigenesis, Genetic; Fluorouracil; Humans; Molecular Targeted Therapy; Neoplasms; Prognosis; Promoter Regions, Genetic; Tumor Suppressor Proteins | 2016 |
The p53 protein plays a central role in the mechanism of action of epigentic drugs that alter the methylation of cytosine residues in DNA.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Cell Death; Cytosine; Decitabine; DNA Methylation; DNA, Neoplasm; Drug Resistance, Neoplasm; Epigenesis, Genetic; Humans; Mutation; Neoplasms; Tumor Suppressor Protein p53 | 2017 |
DNA Hypomethylating Drugs in Cancer Therapy.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Clinical Trials as Topic; Decitabine; DNA Demethylation; Humans; Neoplasms; Tumor Microenvironment | 2017 |
Clinical and biological effects of demethylating agents on solid tumours - A systematic review.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cytidine; Decitabine; DNA Methylation; Humans; Hydralazine; Immune System; Methylation; Neoplasms; Procaine; Treatment Outcome | 2017 |
Epigenetic therapy of leukemia: An update.
Topics: Acetylation; Antineoplastic Agents; Azacitidine; Decitabine; DNA Methylation; Enzyme Inhibitors; Epigenesis, Genetic; Histone Deacetylase Inhibitors; Histone Deacetylases; Histones; Humans; Leukemia; Neoplasms | 2009 |
Decitabine.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Modification Methylases; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Primary Myelofibrosis; Stem Cell Transplantation; Transplantation, Homologous | 2010 |
Epigenetic changes in the myelodysplastic syndrome.
Topics: Acetylation; Acute Disease; Azacitidine; Cell Transformation, Neoplastic; Decitabine; DNA Methylation; Epigenesis, Genetic; Histone Deacetylase Inhibitors; Histone Deacetylases; Histones; Humans; Leukemia, Myeloid; Methylation; Myelodysplastic Syndromes; Neoplasms; Protein Processing, Post-Translational | 2010 |
Targeting DNA methylation for epigenetic therapy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Clinical Trials as Topic; DNA Methylation; DNA Modification Methylases; Epigenesis, Genetic; Female; Humans; Molecular Targeted Therapy; Myelodysplastic Syndromes; Neoplasms | 2010 |
DNA methylation and cancer.
Topics: Animals; Antineoplastic Agents; Azacitidine; CpG Islands; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA, Neoplasm; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Gene Silencing; Genes, Tumor Suppressor; Humans; Neoplasms | 2010 |
Epigenetic drug discovery: targeting DNA methyltransferases.
Topics: Antineoplastic Agents; Azacitidine; Decitabine; DNA Methylation; DNA Modification Methylases; Drug Discovery; Enzyme Inhibitors; Epigenesis, Genetic; Humans; Neoplasms | 2012 |
Will DNA methylation inhibitors work in solid tumors? A review of the clinical experience with azacitidine and decitabine in solid tumors.
Topics: Azacitidine; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Modification Methylases; Dose-Response Relationship, Drug; Epigenesis, Genetic; Histone Deacetylase Inhibitors; Humans; Immunotherapy; Molecular Structure; Neoplasms | 2010 |
5-azacytosine compounds in medicinal chemistry: current stage and future perspectives.
Topics: Animals; Anti-HIV Agents; Antineoplastic Agents; Azacitidine; Cytosine; DNA Methylation; Drug Discovery; HIV; HIV Infections; Humans; Neoplasms | 2012 |
DNA methylation biomarkers in cancer: progress towards clinical implementation.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Biomarkers, Tumor; Decitabine; DNA Methylation; Early Detection of Cancer; Genetic Markers; Humans; Neoplasms; Promoter Regions, Genetic | 2012 |
5-Azacytidine and 5-aza-2'-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Methylation; DNA Modification Methylases; DNA, Neoplasm; Enzyme Inhibitors; Humans; Neoplasms | 2002 |
Reactivating the expression of methylation silenced genes in human cancer.
Topics: Antineoplastic Agents; Azacitidine; Decitabine; DNA Methylation; DNA Modification Methylases; DNA, Neoplasm; Enzyme Inhibitors; Gene Silencing; Genes, Tumor Suppressor; Histone Deacetylase Inhibitors; Humans; Neoplasms; Promoter Regions, Genetic | 2002 |
[DNA methylation and cancer--DNA methylation as a target of cancer chemotherapy].
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; CpG Islands; Decitabine; DNA Methylation; Epigenesis, Genetic; Gene Silencing; Genes, Tumor Suppressor; Humans; Mice; Neoplasms; Point Mutation; Repressor Proteins | 2003 |
Zebularine: a new drug for epigenetic therapy.
Topics: Azacitidine; Cytidine; DNA Methylation; Epigenesis, Genetic; Genetic Therapy; Humans; Neoplasms; Pyrimidine Nucleosides | 2004 |
Decitabine. MGI Pharma Inc/SuperGen Inc.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials as Topic; Decitabine; DNA Modification Methylases; Drug Evaluation, Preclinical; Humans; Neoplasms | 2004 |
Decitabine dosing schedules.
Topics: Azacitidine; Decitabine; Dose-Response Relationship, Drug; Drug Administration Routes; Drug Administration Schedule; Humans; Neoplasms; Treatment Outcome | 2005 |
The epigenome as a molecular marker and target.
Topics: Azacitidine; Biomarkers, Tumor; Cell Cycle; Cell Transformation, Neoplastic; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3B; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Neoplasms; Protein Processing, Post-Translational | 2005 |
Epigenetic drugs: a longstanding story.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cell Differentiation; Decitabine; DNA Methylation; Drug Design; Drug Industry; Epigenesis, Genetic; History, 20th Century; Humans; Models, Chemical; Neoplasms; Pharmacogenetics; Prognosis; Time Factors | 2005 |
Epigenetic therapy of cancer with 5-aza-2'-deoxycytidine (decitabine).
Topics: Alleles; Animals; Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Tumor; Cellular Senescence; Clinical Trials as Topic; Decitabine; Disease Models, Animal; DNA; DNA Methylation; Dose-Response Relationship, Drug; Epigenesis, Genetic; Gene Silencing; Genes, Tumor Suppressor; Humans; Models, Biological; Models, Chemical; Neoplasms; Phenotype; Phosphorylation; Prodrugs; S Phase; Time Factors | 2005 |
Innovative approaches to the clinical development of DNA methylation inhibitors as epigenetic remodeling drugs.
Topics: Antineoplastic Agents; Azacitidine; Clinical Trials as Topic; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Gene Silencing; Histone Deacetylase Inhibitors; Humans; Neoplasms | 2005 |
Clinical development of decitabine as a prototype for an epigenetic drug program.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azacitidine; Clinical Trials as Topic; Decitabine; DNA Adducts; Enzyme Inhibitors; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Gene Silencing; Histone Deacetylase Inhibitors; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Neoplasms; Remission Induction; Time Factors; Treatment Outcome | 2005 |
Epigenetic treatment of hematopoietic malignancies: in vivo targets of demethylating agents.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Azacitidine; Cell Cycle Proteins; Cyclin-Dependent Kinase Inhibitor p15; Decitabine; DNA; DNA Methylation; DNA Modification Methylases; Epigenesis, Genetic; Gene Silencing; Hematologic Neoplasms; Herpesvirus 4, Human; Humans; Leukemia, Myeloid, Acute; Membrane Proteins; Models, Genetic; Neoplasms; Time Factors; Tumor Suppressor Proteins | 2005 |
DNA methylation and gene silencing in cancer.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Methylation; DNA Modification Methylases; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Neoplasms | 2005 |
Decitabine--bedside to bench.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Methylation; Enzyme Inhibitors; Gene Silencing; Humans; Methyltransferases; Molecular Structure; Neoplasms | 2007 |
DNA methylation as a therapeutic target in cancer.
Topics: Antineoplastic Agents; Azacitidine; Base Sequence; Clinical Trials as Topic; Decitabine; DNA Methylation; Gene Expression Regulation, Neoplastic; Humans; Models, Biological; Molecular Sequence Data; Neoplasms | 2007 |
Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Methylation; DNA Modification Methylases; Enzyme Activation; Enzyme Inhibitors; Epigenesis, Genetic; Humans; Neoplasms | 2008 |
Thymidine as an anticancer agent, alone or in combination. A biochemical appraisal.
Topics: Animals; Antineoplastic Agents; Azacitidine; Cytarabine; Decitabine; Drug Therapy, Combination; Fluorouracil; Humans; Methotrexate; Neoplasms; Thymidine | 1982 |
5-methylcytosine, gene regulation, and cancer.
Topics: 5-Methylcytosine; Animals; Azacitidine; Base Sequence; Carcinogens; Cell Transformation, Neoplastic; Cytosine; DNA (Cytosine-5-)-Methyltransferases; DNA Replication; Fibroblasts; Gene Expression Regulation; Humans; Models, Biological; Muscles; Neoplasms; Oncogenes | 1983 |
Altered methionine metabolism, DNA methylation and oncogene expression in carcinogenesis. A review and synthesis.
Topics: Adenosine; Animals; Azacitidine; Carcinogens; Cell Line; Cell Transformation, Neoplastic; Cell Transformation, Viral; Choline; DNA; DNA (Cytosine-5-)-Methyltransferases; DNA, Viral; Ethionine; Gene Expression Regulation; Homocysteine; Humans; Methionine; Methylation; Methyltransferases; Neoplasms; Oncogenes; Oncogenic Viruses; S-Adenosylhomocysteine; S-Adenosylmethionine; Simian virus 40 | 1984 |
Possible epigenetic mechanisms of tumor progression: induction of high-frequency heritable but phenotypically unstable changes in the tumorigenic and metastatic properties of tumor cell populations by 5-azacytidine treatment.
Topics: Animals; Azacitidine; DNA; Ethyl Methanesulfonate; Humans; Mammary Neoplasms, Experimental; Methylation; Methylnitronitrosoguanidine; Models, Genetic; Mutation; Neoplasm Metastasis; Neoplasms; Neoplastic Stem Cells; Phenotype; Stem Cells | 1984 |
The relationship of DNA methylation to cancer.
Topics: 5-Methylcytosine; Azacitidine; CpG Islands; Cytosine; Decitabine; DNA Methylation; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; Methyltransferases; Neoplasms | 1996 |
Drug-induced DNA hypermethylation: a potential mediator of acquired drug resistance during cancer chemotherapy.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Azacitidine; Cells, Cultured; Cisplatin; Decitabine; DNA Methylation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Humans; Neoplasms; Topoisomerase II Inhibitors | 1997 |
DNA methylation: past, present and future directions.
Topics: 5-Methylcytosine; Antimetabolites, Antineoplastic; Azacitidine; Carcinogens; Chromatin; Cytosine; DNA Methylation; DNA Repair; Forecasting; Gene Expression; Humans; Neoplasms | 2000 |
DNA methylation and cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; CpG Islands; Decitabine; DNA Methylation; DNA, Neoplasm; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; Mutation; Neoplasms; Oncogenes | 2000 |
Review of the clinical experience with 5-azacytidine and 5-aza-2'-deoxycytidine in solid tumors.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials as Topic; Decitabine; DNA Methylation; Hematologic Agents; Hematologic Diseases; Humans; Neoplasms | 2002 |
New antineoplastic drugs and their proper use.
Topics: Antineoplastic Agents; Asparaginase; Azacitidine; Bleomycin; Bone Marrow Diseases; Dacarbazine; Doxorubicin; Humans; Liver; Nausea; Neoplasms; Nitrosourea Compounds; Pancreatitis; Pulmonary Fibrosis; Vomiting | 1976 |
Investigational drugs under study by the United States National Cancer Institute.
Topics: Acrylates; Alkylating Agents; Ancitabine; Animals; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Azacitidine; Chemical Phenomena; Chemistry; Chromomycins; Cisplatin; DNA, Neoplasm; Drug Evaluation, Preclinical; Etoposide; Humans; Ifosfamide; Leukemia L1210; Mice; Mitosis; National Institutes of Health (U.S.); Neoplasms; Neoplasms, Experimental; Razoxane; Tegafur; Teniposide; United States | 1976 |
5-azacytidine--a new anticancer drug with significant activity in acute myeloblastic leukemia.
Topics: Abortifacient Agents; Animals; Antineoplastic Agents; Azacitidine; Bacteria; Chemical Phenomena; Chemistry; Drug Resistance; Humans; Leukemia, Myeloid, Acute; Leukopenia; Mutagens; Neoplasms; Species Specificity | 1977 |
Current investigational drugs of interest in the Chemotherapy Program of the National Cancer Institute.
Topics: Altretamine; Animals; Antineoplastic Agents; Asparaginase; Azacitidine; Bleomycin; Cisplatin; Dacarbazine; Doxorubicin; Drug Evaluation; Female; Guanazole; Humans; Ifosfamide; Male; National Institutes of Health (U.S.); Neoplasms; Nitrogen Mustard Compounds; Nitrosourea Compounds; Razoxane; United States | 1977 |
New anticancer agents.
Topics: Alkaloids; Animals; Antineoplastic Agents; Azacitidine; Biphenyl Compounds; Chrysenes; Deoxycytidine; Echinomycin; Epirubicin; Etanidazole; Flavonoids; Gemcitabine; Guanidines; Humans; Idarubicin; Menogaril; Mitoguazone; Neoplasms; Nitroimidazoles; Nogalamycin; Organoplatinum Compounds; Paclitaxel; Pentostatin; Polymers; Propylene Glycols; Ribavirin; Sulfonylurea Compounds; Trimetrexate; Vidarabine Phosphate | 1991 |
DNA methylation and cancer.
Topics: Animals; Azacitidine; Cell Division; DNA (Cytosine-5-)-Methyltransferases; DNA Replication; DNA, Neoplasm; Eukaryotic Cells; Gene Expression Regulation; Humans; Methylation; Neoplasms | 1986 |
Tumors as caricatures of the process of tissue renewal: prospects for therapy by directing differentiation.
Topics: Azacitidine; Cell Differentiation; Colony-Stimulating Factors; Embryonic Induction; Humans; Neoplasms; Peptides; Transforming Growth Factors; Tretinoin | 1988 |
Hypomethylation of DNA in the regulation of gene expression.
Topics: 5-Methylcytosine; Animals; Azacitidine; Cell Differentiation; Cytosine; DNA; Gene Expression Regulation; Humans; Methylation; Methyltransferases; Neoplasms | 1988 |
Altering gene expression with 5-azacytidine.
Topics: Anemia, Sickle Cell; Animals; Azacitidine; Cell Differentiation; Cell Line; DNA; Embryo, Mammalian; Embryo, Nonmammalian; Fetal Hemoglobin; Gene Expression Regulation; Genes; Genes, Regulator; Methylation; Mutation; Neoplasms; Thalassemia; Thymidine Kinase | 1985 |
24 trial(s) available for azacitidine and Neoplasms
| Article | Year |
|---|---|
Phase I/II sequencing study of azacitidine, epacadostat, and pembrolizumab in advanced solid tumors.
Topics: Azacitidine; Humans; Immune Checkpoint Inhibitors; Interferons; Neoplasms | 2023 |
Increased IFNγ
Topics: Animals; Antineoplastic Agents; Azacitidine; Cell Line, Tumor; Cytotoxicity, Immunologic; Decitabine; Disease Models, Animal; Disease Progression; DNA Methylation; Dose-Response Relationship, Drug; Epigenesis, Genetic; Female; Humans; Interferon-gamma; Lymphocyte Activation; Male; Mice; Neoplasms; Survival Analysis; T-Lymphocyte Subsets; T-Lymphocytes, Cytotoxic; Th1 Cells; Treatment Outcome; Xenograft Model Antitumor Assays | 2017 |
A phase 1 trial of the oral DNA methyltransferase inhibitor CC-486 and the histone deacetylase inhibitor romidepsin in advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Depsipeptides; DNA Modification Methylases; Drug Administration Schedule; Female; Histone Deacetylase Inhibitors; Humans; Long Interspersed Nucleotide Elements; Male; Maximum Tolerated Dose; Methyltransferases; Middle Aged; Nausea; Neoplasms | 2019 |
Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies.
Topics: Acetylation; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Carboplatin; DNA Methylation; Female; Histone Deacetylase Inhibitors; Histones; Humans; Male; Middle Aged; Neoplasms; Receptors, TNF-Related Apoptosis-Inducing Ligand; Valproic Acid | 2013 |
Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers.
Topics: Azacitidine; Cell Line, Tumor; DNA (Cytosine-5-)-Methyltransferases; DNA, Neoplasm; Epigenomics; Gene Expression Regulation, Neoplastic; Humans; Neoplasms | 2014 |
A phase I study in patients with solid or hematologic malignancies of the dose proportionality of subcutaneous Azacitidine and its pharmacokinetics in patients with severe renal impairment.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Dose-Response Relationship, Drug; Female; Hematologic Neoplasms; Humans; Injections, Subcutaneous; Male; Middle Aged; Neoplasms; Renal Insufficiency; Severity of Illness Index; Time Factors | 2014 |
Low-dose decitabine-based chemoimmunotherapy for patients with refractory advanced solid tumors: a phase I/II report.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Carcinoma; Combined Modality Therapy; Cyclophosphamide; Decitabine; DNA Methylation; DNA Modification Methylases; Double-Blind Method; Doxorubicin; Female; Humans; Immunotherapy; Killer Cells, Natural; Lymphoma; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms; Prednisone; Prospective Studies; Survival Analysis; Vincristine | 2014 |
Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Child; Cohort Studies; CpG Islands; DNA Methylation; Drug Synergism; Epigenesis, Genetic; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Valproic Acid | 2008 |
Decitabine effect on tumor global DNA methylation and other parameters in a phase I trial in refractory solid tumors and lymphomas.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Blood Pressure; Cation Transport Proteins; Copper Transporter 1; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Modification Methylases; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Hydrogen-Ion Concentration; In Situ Nick-End Labeling; Ki-67 Antigen; Leukocytes, Mononuclear; Lymphoma; Male; Middle Aged; Neoplasms; Sex Factors; Treatment Outcome; Young Adult | 2009 |
A phase I dose-finding study of 5-azacytidine in combination with sodium phenylbutyrate in patients with refractory solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; DNA Modification Methylases; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Histone Acetyltransferases; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Phenylbutyrates; Treatment Outcome | 2009 |
Phase I study of decitabine with doxorubicin and cyclophosphamide in children with neuroblastoma and other solid tumors: a Children's Oncology Group study.
Topics: Adolescent; Adult; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Caspase 8; Child; Child, Preschool; Cyclophosphamide; Decitabine; DNA Methylation; Doxorubicin; Female; Fetal Hemoglobin; Gene Expression Profiling; Humans; Infant; Male; Melanoma-Specific Antigens; Neoplasm Proteins; Neoplasms; Neuroblastoma | 2010 |
Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; CpG Islands; Decitabine; Disease Progression; DNA Methylation; Epigenesis, Genetic; Female; Humans; Hydroxamic Acids; Lymphoma, Non-Hodgkin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Promoter Regions, Genetic; Time Factors; Vorinostat | 2011 |
A phase I study of 5-azacytidine and erlotinib in advanced solid tumor malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cohort Studies; Conjunctivitis; Diarrhea; Disease-Free Survival; Erlotinib Hydrochloride; Exanthema; Fatigue; Female; Humans; Male; Middle Aged; Nausea; Neoplasms; Quinazolines; Treatment Outcome | 2012 |
Phase I trial of continuous infusion 5-aza-2'-deoxycytidine.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Biopsy; Decitabine; DNA Methylation; DNA, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Polymerase Chain Reaction | 2003 |
Evaluation of a 7-day continuous intravenous infusion of decitabine: inhibition of promoter-specific and global genomic DNA methylation.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Methylation; DNA Modification Methylases; Drug Administration Schedule; Drug Evaluation; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Promoter Regions, Genetic | 2005 |
Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Azacitidine; Carboplatin; Cohort Studies; CpG Islands; Decitabine; DNA Methylation; DNA Modification Methylases; Female; Humans; Male; Middle Aged; Neoplasms | 2007 |
Phase I study using combination of hydroxyurea and 5-azacytidine (NSC-102816).
Topics: Adult; Aged; Azacitidine; Bone Marrow; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Hydroxyurea; Leukemia; Middle Aged; Neoplasms; Time Factors | 1980 |
A phase I trial of fazarabine in refractory pediatric solid tumors. A Pediatric Oncology Group study.
Topics: Antineoplastic Agents; Azacitidine; Child; Child, Preschool; Drug Administration Schedule; Humans; Neoplasms | 1993 |
Phase I and pharmacological trial of fazarabine (Ara-AC) with granulocyte colony-stimulating factor.
Topics: Adult; Antineoplastic Agents; Azacitidine; Dose-Response Relationship, Drug; Female; Granulocyte Colony-Stimulating Factor; Humans; Male; Metabolic Clearance Rate; Nausea; Neoplasms; Neutropenia | 1997 |
A phase I study of 5-azacytidine (NSC-102816).
Topics: Azacitidine; Clinical Trials as Topic; Drug Administration Schedule; Humans; Neoplasms | 1976 |
Phase I trial of a 72-h continuous-infusion schedule of fazarabine.
Topics: Adult; Aged; Antineoplastic Agents; Azacitidine; Drug Administration Schedule; Drug Evaluation; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms | 1992 |
Phase I and pharmacokinetic study of arabinofuranosyl-5-azacytosine (fazarabine, NSC 281272).
Topics: Adult; Aged; Antineoplastic Agents; Azacitidine; Clinical Trials as Topic; Drug Administration Schedule; Drug Evaluation; Female; Humans; Leukopenia; Male; Middle Aged; Neoplasms; Neutropenia; Thrombocytopenia | 1990 |
Phase I clinical trial of fazarabine as a twenty-four-hour continuous infusion.
Topics: Adult; Aged; Antineoplastic Agents; Azacitidine; Dose-Response Relationship, Drug; Humans; Infusions, Intravenous; Metabolic Clearance Rate; Middle Aged; Neoplasms | 1991 |
The EORTC Early Clinical Trials Cooperative Group experience with 5-aza-2'-deoxycytidine (NSC 127716) in patients with colo-rectal, head and neck, renal carcinomas and malignant melanomas.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Azacitidine; Carcinoma, Squamous Cell; Clinical Trials as Topic; Decitabine; Female; Hematologic Diseases; Humans; Male; Melanoma; Middle Aged; Neoplasms | 1987 |
130 other study(ies) available for azacitidine and Neoplasms
| Article | Year |
|---|---|
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Single-agent 5-azacytidine as post-transplant maintenance in high-risk myeloid malignancies undergoing allogeneic hematopoietic cell transplantation.
Topics: Azacitidine; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Myeloproliferative Disorders; Neoplasms; Prospective Studies; Recurrence; Retrospective Studies; Transplantation Conditioning | 2022 |
Selinexor synergizes with azacitidine to eliminate myelodysplastic syndrome cells through p53 nuclear accumulation.
Topics: Azacitidine; Humans; Hydrazines; Myelodysplastic Syndromes; Neoplasms; Triazoles; Tumor Suppressor Protein p53 | 2022 |
Resurgence of myeloproliferative neoplasm in patients in remission from blast transformation after treatment with hypomethylating agents.
Topics: Azacitidine; Humans; Janus Kinase 2; Leukemia; Lymphocyte Activation; Mutation; Myeloproliferative Disorders; Neoplasms; Recurrence | 2022 |
Dual targeting of aberrant DNA and histone methylation synergistically suppresses tumor cell growth in ATL.
Topics: Adult; Azacitidine; DNA; DNA Methylation; Histones; Human T-lymphotropic virus 1; Humans; Leukemia-Lymphoma, Adult T-Cell; Neoplasms | 2023 |
Inhibition of lysyl oxidases synergizes with 5-azacytidine to restore erythropoiesis in myelodysplastic and myeloid malignancies.
Topics: Animals; Azacitidine; Erythropoiesis; Female; Hematopoietic Stem Cells; Humans; Mice; Myelodysplastic Syndromes; Myeloproliferative Disorders; Neoplasms; Protein-Lysine 6-Oxidase | 2023 |
Postazacitidine clone size predicts long-term outcome of patients with myelodysplastic syndromes and related myeloid neoplasms.
Topics: Azacitidine; Humans; Myelodysplastic Syndromes; Myeloproliferative Disorders; Neoplasms; Prognosis; Treatment Outcome | 2023 |
Epigenetic therapy inhibits metastases by disrupting premetastatic niches.
Topics: Animals; Azacitidine; Benzamides; Cell Differentiation; Cell Movement; Chemotherapy, Adjuvant; Disease Models, Animal; Down-Regulation; Epigenesis, Genetic; Genetic Therapy; Mice; Myeloid-Derived Suppressor Cells; Neoplasm Metastasis; Neoplasms; Pyridines; Receptors, CCR2; Receptors, Interleukin-8B; Tumor Microenvironment | 2020 |
A retrospective analysis of dermatological problems in haematology and oncology patients at a tertiary Singapore hospital.
Topics: Antibodies, Bispecific; Antineoplastic Agents; Azacitidine; Bortezomib; ErbB Receptors; Hematologic Diseases; Humans; Immunotherapy; Neoplasms; Pemetrexed; Pyrimidines; Retrospective Studies; Singapore; Skin Diseases; Tertiary Care Centers | 2020 |
Cancer testis antigens in myelodysplastic syndromes revisited: a targeted RNA-seq approach.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Humans; Male; Myelodysplastic Syndromes; Neoplasms; Sequence Analysis, RNA; Testis; Transcription Factor DP1 | 2020 |
DNA methylation inhibitors: Retrospective and perspective view.
Topics: Antineoplastic Agents; Azacitidine; DNA Methylation; Humans; Neoplasms; Retrospective Studies | 2021 |
Demethylating agent decitabine disrupts tumor-induced immune tolerance by depleting myeloid-derived suppressor cells.
Topics: Animals; Apoptosis; Azacitidine; Cell Line, Tumor; Decitabine; Humans; Immune Tolerance; Lymphocyte Activation; Mice; Myeloid-Derived Suppressor Cells; Neoplasms; T-Lymphocytes | 2017 |
Non-homologous end joining induced alterations in DNA methylation: A source of permanent epigenetic change.
Topics: Alleles; Azacitidine; Cell Line, Tumor; Cell Transformation, Neoplastic; CpG Islands; Decitabine; DNA Breaks, Double-Stranded; DNA End-Joining Repair; DNA Methylation; Doxycycline; Epigenesis, Genetic; Green Fluorescent Proteins; HeLa Cells; Humans; Neoplasms | 2017 |
Expansion of cancer germline antigen-specific cytotoxic T lymphocytes for immunotherapy.
Topics: Antigens, Neoplasm; Azacitidine; Decitabine; Dendritic Cells; Epitopes; Germ Cells; Humans; Immunotherapy, Adoptive; Interferon-gamma; Interleukins; Melanoma-Specific Antigens; Membrane Proteins; Neoplasm Proteins; Neoplasms; T-Lymphocytes, Cytotoxic | 2017 |
DNA methylation protects against cisplatin-induced kidney injury by regulating specific genes, including interferon regulatory factor 8.
Topics: Acute Kidney Injury; Animals; Antineoplastic Agents; Apoptosis; Azacitidine; Cell Line; Cisplatin; Decitabine; Disease Models, Animal; DNA (Cytosine-5-)-Methyltransferase 1; DNA Methylation; Epigenesis, Genetic; Gene Knockdown Techniques; Genome; Humans; Interferon Regulatory Factors; Kidney Tubules, Proximal; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Neoplasms; Rats; Sequence Analysis, DNA | 2017 |
Nicotine Exposure Augments Renal Toxicity of 5-aza-cytidine Through p66shc: Prevention by Resveratrol.
Topics: Antioxidants; Azacitidine; Cell Line; Heme Oxygenase-1; Humans; Kidney Tubules, Proximal; Neoplasms; NF-E2-Related Factor 2; Nicotine; Oxidative Stress; Promoter Regions, Genetic; Resveratrol; Signal Transduction; Src Homology 2 Domain-Containing, Transforming Protein 1; Stilbenes | 2017 |
Induction of senescence in cancer cells by 5'-Aza-2'-deoxycytidine: Bioinformatics and experimental insights to its targets.
Topics: Antineoplastic Agents; Azacitidine; Cell Death; Cell Line, Tumor; Cell Proliferation; Cellular Senescence; Computational Biology; Decitabine; Dose-Response Relationship, Drug; Humans; Neoplasms; Signal Transduction; Structure-Activity Relationship; Tumor Suppressor Protein p53 | 2017 |
Tumor suppressor activity of miR-451: Identification of CARF as a new target.
Topics: A549 Cells; Animals; Azacitidine; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Decitabine; DNA-Binding Proteins; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Mice; MicroRNAs; Neoplasm Transplantation; Neoplasms; Oligonucleotide Array Sequence Analysis; Signal Transduction; Transcription Factors; Up-Regulation | 2018 |
Development, validation, and clinical application of a high-performance liquid chromatography-tandem mass spectrometry assay for the quantification of total intracellular β-decitabine nucleotides and genomic DNA incorporated β-decitabine and 5-methyl-2'-d
Topics: Adult; Antimetabolites, Antineoplastic; Azacitidine; Chromatography, High Pressure Liquid; Clinical Trials, Phase II as Topic; Decitabine; Deoxycytidine; DNA; DNA Methylation; Humans; Leukocytes, Mononuclear; Limit of Detection; Neoplasms; Randomized Controlled Trials as Topic; Tandem Mass Spectrometry | 2019 |
Circulating cell-free DNA release in vitro: kinetics, size profiling, and cancer-related gene methylation.
Topics: Azacitidine; Biomarkers, Tumor; Cell-Free Nucleic Acids; DNA Methylation; HeLa Cells; Humans; Kinetics; MCF-7 Cells; Neoplasms | 2019 |
Interferon-regulated suprabasin is essential for stress-induced stem-like cell conversion and therapy resistance of human malignancies.
Topics: Animals; Anoikis; Antigens, Differentiation; Antineoplastic Agents; Azacitidine; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Interferons; Mice; Mice, Inbred BALB C; Neoplasm Proteins; Neoplasms; Neoplastic Stem Cells; Up-Regulation | 2019 |
Novel prodrugs of decitabine with greater metabolic stability and less toxicity.
Topics: Animals; Area Under Curve; Azacitidine; Blood Chemical Analysis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Decitabine; DNA Methylation; Drug Stability; Gene Expression Regulation, Neoplastic; Injections, Intraperitoneal; Mice; Neoplasms; Prodrugs; Xenograft Model Antitumor Assays | 2019 |
Epigenetic cancer therapies emerge out of the lab into the limelight.
Topics: Antineoplastic Agents; Azacitidine; Benzamides; Clinical Trials as Topic; Depsipeptides; Drug Resistance, Neoplasm; Epigenomics; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Neoplasms; Pyridines; Vorinostat | 2013 |
EBV-transformed lymphoblastoid cell lines as vaccines against cancer testis antigen-positive tumors.
Topics: Antigen-Presenting Cells; Antigens, Neoplasm; Azacitidine; B-Lymphocytes; Cancer Vaccines; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Line, Transformed; Cell Line, Tumor; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; Gene Expression Regulation, Neoplastic; Herpesvirus 4, Human; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Interferon-gamma; Melanoma; Neoplasms; RNA, Messenger; Telomerase; Telomere; Tumor Necrosis Factor-alpha; Valproic Acid; Vorinostat | 2013 |
Differential induction of apoptosis and senescence by the DNA methyltransferase inhibitors 5-azacytidine and 5-aza-2'-deoxycytidine in solid tumor cells.
Topics: Apoptosis; Azacitidine; Cell Line, Tumor; Cell Proliferation; Cellular Senescence; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Breaks, Double-Stranded; DNA Methylation; Hep G2 Cells; Humans; Neoplasms; Tumor Suppressor Protein p53 | 2013 |
Different involvement of promoter methylation in the expression of organic cation/carnitine transporter 2 (OCTN2) in cancer cell lines.
Topics: Animals; Azacitidine; Base Sequence; Cell Line, Tumor; Cell Survival; Chlorocebus aethiops; COS Cells; CpG Islands; Decitabine; DNA Methylation; Gene Expression Regulation, Neoplastic; Genes, Reporter; Genome, Human; Humans; Luciferases; Molecular Sequence Data; Neoplasms; Organic Cation Transport Proteins; Organoplatinum Compounds; Oxaliplatin; Polymerase Chain Reaction; Promoter Regions, Genetic; RNA, Messenger; Solute Carrier Family 22 Member 5; Transcription, Genetic | 2013 |
5-Aza-CdR delivers a gene body blow.
Topics: Azacitidine; DNA Methylation; Down-Regulation; Gene Expression; Humans; Neoplasms | 2014 |
Identification of coexistence of DNA methylation and H3K27me3 specifically in cancer cells as a promising target for epigenetic therapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Benzamides; Cell Proliferation; Decitabine; DNA Methylation; Enhancer of Zeste Homolog 2 Protein; Enzyme Inhibitors; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; HCT116 Cells; Histone Deacetylase Inhibitors; Histones; Humans; Indoles; Insulin-Like Growth Factor Binding Proteins; Intercellular Signaling Peptides and Proteins; Male; MCF-7 Cells; Membrane Proteins; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Polycomb Repressive Complex 2; Promoter Regions, Genetic; Pyridines; Pyridones; Xenograft Model Antitumor Assays | 2015 |
A robust and rapid liquid chromatography tandem mass spectrometric method for the quantitative analysis of 5-azacytidine.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Chromatography, Liquid; Drug Stability; Humans; Neoplasms; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry | 2016 |
Tolerability of Vidaza (azacitidine) subcutaneous administration using a maximum volume of 3 ml per injection.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Female; Humans; Injections, Subcutaneous; Male; Middle Aged; Neoplasms; Prospective Studies; Syringes | 2016 |
Perspectives in Medicinal Chemistry: DNA Methylation and Demethylation Mechanisms as Therapeutic Targets?
Topics: Azacitidine; Chemistry, Pharmaceutical; Decitabine; DNA Glycosylases; DNA Methylation; Endodeoxyribonucleases; Epigenesis, Genetic; Humans; Neoplasms | 2016 |
Epigenetic Modulators and the New Immunotherapies.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Enzyme Inhibitors; Epigenesis, Genetic; Gene Expression; Humans; Immunotherapy; Mice; Neoplasms | 2016 |
DNA demethylating agent decitabine broadens the peripheral T cell receptor repertoire.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Azacitidine; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Complementarity Determining Regions; Decitabine; DNA Methylation; Epigenesis, Genetic; Female; Humans; Immunotherapy; Male; Middle Aged; Neoplasms; Receptors, Antigen, T-Cell, alpha-beta; T-Lymphocytes | 2016 |
Nephrotoxicity of epigenetic inhibitors used for the treatment of cancer.
Topics: Acetylation; Animals; Antineoplastic Agents; Azacitidine; Cell Death; Cell Line, Tumor; Cell Proliferation; Cisplatin; Cyclin-Dependent Kinase Inhibitor p21; Docetaxel; Epigenesis, Genetic; HEK293 Cells; Histones; Humans; Hydroxamic Acids; Kidney; Male; Methylation; Neoplasms; Oligopeptides; Prostatic Neoplasms; Rats; Taxoids | 2016 |
A cross-talk between DNA methylation and H3 lysine 9 dimethylation at the KvDMR1 region controls the induction of Cdkn1c in muscle cells.
Topics: Azacitidine; Cell Differentiation; Cell Line, Tumor; Chromatin; Cyclin-Dependent Kinase Inhibitor p57; DNA Methylation; Epigenesis, Genetic; Gene Expression Regulation, Developmental; Genomic Imprinting; Histone Demethylases; Humans; Muscle Development; Muscle, Skeletal; MyoD Protein; Neoplasms; Potassium Channels, Voltage-Gated; Promoter Regions, Genetic | 2016 |
Use of 5-azacitidine for therapy-related myeloid neoplasms in patients with concomitant active neoplastic disease.
Topics: Adult; Aged; Aged, 80 and over; Azacitidine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Neoplasms, Second Primary; Remission Induction; Retrospective Studies; Survival Rate; Treatment Outcome | 2017 |
[Predict response to decitabine in patients with myelodysplastic syndrome and related neoplasms].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Azacitidine; Chromosome Aberrations; Chromosomes, Human, Pair 7; Decitabine; Female; Humans; Karyotype; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Neoplasms; Remission Induction; Retrospective Studies; Young Adult | 2017 |
5-Aza-2'-deoxycytidine restores proapoptotic function of p53 in cancer cells resistant to p53-induced apoptosis.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Apoptosis Regulatory Proteins; Azacitidine; Cell Cycle; Cell Proliferation; Decitabine; DNA Modification Methylases; Gene Expression Regulation, Neoplastic; HCT116 Cells; Humans; Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; RNA Interference; Time Factors; Tumor Suppressor Protein p53 | 2008 |
Alterations of constitutive pericentromeric heterochromatin in lymphocytes of cancer patients and lymphocytes exposed to 5-azacytidine is associated with DNA-hypomethylation.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Case-Control Studies; Centromere; Chromosomes, Human; DNA Methylation; DNA, Neoplasm; Heterochromatin; Humans; In Situ Hybridization, Fluorescence; Lymphocytes; Metaphase; Neoplasms; Ploidies | 2008 |
Aberrant methylation of human L- and M-fructose 1,6-bisphosphatase genes in cancer.
Topics: Adult; Aged; Aged, 80 and over; Azacitidine; Breast Neoplasms; Cell Line, Tumor; DNA Methylation; Female; Fructose-Bisphosphatase; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Hydroxamic Acids; Middle Aged; Neoplasms; Promoter Regions, Genetic | 2008 |
Hypomethylating drugs convert HA-1-negative solid tumors into targets for stem cell-based immunotherapy.
Topics: Acetylation; Antigens, Neoplasm; Azacitidine; Cell Line, Tumor; CpG Islands; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA, Neoplasm; Gene Expression Regulation, Neoplastic; Gene Silencing; Histones; Humans; Hydroxamic Acids; Immunotherapy; Minor Histocompatibility Antigens; Neoplasm Proteins; Neoplasms; Oligopeptides; Promoter Regions, Genetic; Protein Processing, Post-Translational; RNA, Messenger; RNA, Neoplasm; T-Lymphocytes, Cytotoxic; Transcription, Genetic | 2009 |
Epigenetic therapy upregulates the tumor suppressor microRNA-126 and its host gene EGFL7 in human cancer cells.
Topics: Antineoplastic Agents; Azacitidine; Calcium-Binding Proteins; Cell Line, Tumor; Decitabine; EGF Family of Proteins; Endothelial Growth Factors; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; Male; MicroRNAs; Neoplasms; Phenylbutyrates; Promoter Regions, Genetic; Prostatic Neoplasms; Up-Regulation; Urinary Bladder Neoplasms | 2009 |
Promoter CpG methylation in cancer cells contributes to the regulation of MUC4.
Topics: Acetylation; Azacitidine; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; DNA Modification Methylases; DNA, Neoplasm; Enzyme Inhibitors; Epigenesis, Genetic; Histone Deacetylase Inhibitors; Histone Deacetylases; Histones; Humans; Hydroxamic Acids; Mucin-4; Neoplasms; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2009 |
Cancer prevention: epigenetics steps up to the plate.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cell Transformation, Neoplastic; Chemoprevention; Cytidine; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Enzyme Inhibitors; Epigenesis, Genetic; Humans; Models, Biological; Neoplasms | 2008 |
LINE-1 methylation in plasma DNA as a biomarker of activity of DNA methylation inhibitors in patients with solid tumors.
Topics: Antigens, Neoplasm; Antimetabolites, Antineoplastic; Azacitidine; Biomarkers, Tumor; Cell Line, Tumor; Cheek; Decitabine; DNA Methylation; DNA Modification Methylases; DNA, Neoplasm; Humans; Long Interspersed Nucleotide Elements; Melanoma-Specific Antigens; Mouth Mucosa; Neoplasm Proteins; Neoplasms; Promoter Regions, Genetic; Saliva; Sequence Analysis, DNA | 2009 |
DNA hypomethylation as Achilles' heel of tumorigenesis: a working hypothesis.
Topics: Azacitidine; DNA Methylation; Epigenesis, Genetic; Heterochromatin; Interphase; Karyotyping; Lymphocytes; Metaphase; Neoplasms; Ploidies | 2009 |
Targeting DNA methylation.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials as Topic; Decitabine; DNA Methylation; DNA Modification Methylases; Epigenesis, Genetic; Humans; Myelodysplastic Syndromes; Neoplasms | 2009 |
Defective interleukin-4/Stat6 activity correlates with increased constitutive expression of negative regulators SOCS-3, SOCS-7, and CISH in colon cancer cells.
Topics: Azacitidine; Caco-2 Cells; Decitabine; DNA Methylation; HT29 Cells; Humans; Interleukin-4; Neoplasms; Nuclear Proteins; Phosphorylation; Promoter Regions, Genetic; RNA, Messenger; Signal Transduction; STAT6 Transcription Factor; Suppressor of Cytokine Signaling 3 Protein; Suppressor of Cytokine Signaling Proteins; Up-Regulation | 2009 |
The novel human endogenous retrovirus-related gene, psiTPTE22-HERV, is silenced by DNA methylation in cancers.
Topics: Azacitidine; Blotting, Western; Chromosomes, Human, Pair 22; Cytoplasm; Decitabine; DNA Methylation; DNA Modification Methylases; Endogenous Retroviruses; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Gene Expression Regulation; Gene Silencing; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Membrane Proteins; Neoplasms; Open Reading Frames; PTEN Phosphohydrolase; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Transcription, Genetic | 2010 |
Expression and regulation mechanisms of Sonic Hedgehog in breast cancer.
Topics: Azacitidine; Breast; Breast Neoplasms; Cell Line, Tumor; DNA Methylation; Female; Hedgehog Proteins; Humans; Immunohistochemistry; Middle Aged; Neoplasms; NF-kappa B; RNA, Messenger; Transcription Factors; Up-Regulation; Zinc Finger Protein GLI1 | 2010 |
Valproic acid in the complex therapy of malignant tumors.
Topics: Acetylation; Angiogenesis Inhibitors; Apoptosis; Azacitidine; Cell Cycle; Clinical Trials as Topic; Combined Modality Therapy; Decitabine; Drug Repositioning; Drug Resistance, Neoplasm; Drug Synergism; Drug Therapy, Combination; Epilepsy; Histone Deacetylase Inhibitors; Histone Deacetylases; Histones; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms; Topoisomerase II Inhibitors; Tumor Suppressor Protein p53; Valproic Acid | 2010 |
S110, a 5-Aza-2'-deoxycytidine-containing dinucleotide, is an effective DNA methylation inhibitor in vivo and can reduce tumor growth.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Tumor; Cell Proliferation; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Down-Regulation; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Models, Biological; Neoplasms; Oligonucleotides; Treatment Outcome; Tumor Burden; Xenograft Model Antitumor Assays | 2010 |
Delivery of 5-azacytidine to human cancer cells by elaidic acid esterification increases therapeutic drug efficacy.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Tumor; Drug Delivery Systems; Epigenesis, Genetic; Esterification; Esters; Gene Expression Regulation, Neoplastic; HCT116 Cells; HL-60 Cells; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Models, Biological; Neoplasms; Oleic Acid; Oleic Acids; Treatment Outcome; Xenograft Model Antitumor Assays | 2010 |
Validation of a novel statistical model for assessing the synergy of combined-agent cancer chemoprevention.
Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Chemoprevention; Decitabine; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Models, Statistical; Neoplasms; Vorinostat | 2010 |
Aberrant demethylation of the recoverin gene is involved in the aberrant expression of recoverin in cancer cells.
Topics: Azacitidine; Cell Line, Tumor; Decitabine; DNA Methylation; DNA Modification Methylases; Exons; Gene Expression Regulation, Neoplastic; Humans; Lung; Melanoma; Neoplasms; Promoter Regions, Genetic; Recoverin; Skin; Small Cell Lung Carcinoma | 2010 |
Measuring topology of low-intensity DNA methylation sites for high-throughput assessment of epigenetic drug-induced effects in cancer cells.
Topics: Antineoplastic Agents; Azacitidine; Cell Line, Tumor; Cell Nucleus; Cytidine; Cytosine; DNA Methylation; DNA, Neoplasm; Epigenesis, Genetic; Fluorescence; High-Throughput Screening Assays; Humans; Indoles; Neoplasms; Nucleic Acid Conformation | 2010 |
Epigenetic regulation of microRNA expression in cancer.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Tumor; DNA Methylation; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Neoplasms | 2011 |
DNA methyltransferase inhibition may limit cancer cell growth by disrupting ribosome biogenesis.
Topics: Azacitidine; Cell Proliferation; CpG Islands; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Enzyme Inhibitors; Gene Silencing; Genes, rRNA; Genes, Tumor Suppressor; Genomic Imprinting; HCT116 Cells; Humans; Neoplasms; Repetitive Sequences, Nucleic Acid; Ribosomes | 2011 |
Increased PRAME antigen-specific killing of malignant cell lines by low avidity CTL clones, following treatment with 5-Aza-2'-Deoxycytidine.
Topics: Antibody Affinity; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Tumor; Cytotoxicity, Immunologic; Decitabine; HL-60 Cells; HLA-A2 Antigen; Humans; Immunotherapy, Adoptive; K562 Cells; Neoplasms; T-Lymphocytes, Cytotoxic; Transfection | 2011 |
Transformation-dependent silencing of tumor-selective apoptosis-inducing TRAIL by DNA hypermethylation is antagonized by decitabine.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Cell Line, Transformed; Cell Line, Tumor; Cell Transformation, Neoplastic; Decitabine; DNA Methylation; Down-Regulation; Enzyme Inhibitors; Epigenesis, Genetic; Gene Expression Regulation; Gene Silencing; HeLa Cells; Humans; Interferons; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Proto-Oncogene Proteins p21(ras); Signal Transduction; TNF-Related Apoptosis-Inducing Ligand; Xenograft Model Antitumor Assays | 2011 |
γ-radiation induces cellular sensitivity and aberrant methylation in human tumor cell lines.
Topics: Ataxia Telangiectasia Mutated Proteins; Azacitidine; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Decitabine; DNA Breaks; DNA Methylation; DNA-Binding Proteins; Gamma Rays; Genes, p16; Humans; Hydroxamic Acids; Neoplasms; Promoter Regions, Genetic; Protein Serine-Threonine Kinases; Radiation Tolerance; Tumor Suppressor Proteins | 2011 |
Azacitidine.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Carcinogens; Humans; Neoplasms | 2011 |
Basic anatomy and tumor biology of the RPS6KA6 gene that encodes the p90 ribosomal S6 kinase-4.
Topics: Alternative Splicing; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Azacitidine; Base Sequence; Blotting, Western; Cell Adhesion; Cell Cycle; Cell Proliferation; Cyclin D1; DNA, Complementary; Exons; Female; Humans; Immunoenzyme Techniques; Immunoprecipitation; Mice; Mice, SCID; Molecular Sequence Data; Neoplasms; Protein Isoforms; Proto-Oncogene Proteins c-myc; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Ribosomal Protein S6 Kinases, 90-kDa; RNA, Messenger; RNA, Small Interfering; Sequence Homology, Nucleic Acid; Transcription Initiation Site; Tumor Cells, Cultured | 2013 |
Immunomodulatory activity of SGI-110, a 5-aza-2'-deoxycytidine-containing demethylating dinucleotide.
Topics: Antigens, Neoplasm; Azacitidine; Cell Line, Tumor; Cytotoxicity, Immunologic; DNA Methylation; Humans; Immunomodulation; Immunophenotyping; Immunotherapy; Melanoma; Neoplasms | 2013 |
DNA methylation associated with polycomb repression in retinoic acid receptor β silencing.
Topics: Azacitidine; Cell Line, Tumor; Chromatin; CpG Islands; Decitabine; DNA Methylation; Enzyme Inhibitors; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Gene Silencing; Histones; Humans; Neoplasms; Promoter Regions, Genetic; Receptors, Retinoic Acid | 2013 |
Deregulation of caspase 8 and 10 expression in pediatric tumors and cell lines.
Topics: Azacitidine; Carrier Proteins; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspase 10; Caspase 8; Caspase 9; Caspases; Child; Decitabine; DNA Methylation; Enzyme Inhibitors; Gene Amplification; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Genes, myc; Genes, Tumor Suppressor; Humans; Hydroxamic Acids; Intracellular Signaling Peptides and Proteins; Neoplasm Proteins; Neoplasms; RNA, Messenger; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2002 |
The human telomerase RNA gene (hTERC) is regulated during carcinogenesis but is not dependent on DNA methylation.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cell Division; Cell Line; Decitabine; DNA Methylation; Gene Expression Regulation, Neoplastic; HeLa Cells; Humans; Neoplasms; Polymorphism, Genetic; Promoter Regions, Genetic; Protein Conformation; Reverse Transcriptase Polymerase Chain Reaction; RNA; Sarcoma; Sulfites; Telomerase; Tumor Cells, Cultured | 2002 |
A systematic profile of DNA methylation in human cancer cell lines.
Topics: 5-Methylcytosine; Azacitidine; Cluster Analysis; CpG Islands; Cytosine; Decitabine; DNA Methylation; DNA, Neoplasm; Genes, Tumor Suppressor; Germ-Line Mutation; Humans; Neoplasms; Oligonucleotide Array Sequence Analysis; Tumor Cells, Cultured | 2003 |
Promoter hypermethylation of DLC-1, a candidate tumor suppressor gene, in several common human cancers.
Topics: Adenocarcinoma; Azacitidine; Base Sequence; Breast Neoplasms; Carcinoma, Hepatocellular; Colonic Neoplasms; CpG Islands; Decitabine; DNA Methylation; DNA, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; GTPase-Activating Proteins; Humans; Liver Neoplasms; Male; Molecular Sequence Data; Neoplasm Proteins; Neoplasms; Promoter Regions, Genetic; Prostatic Neoplasms; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2003 |
Five new human cancer-germline genes identified among 12 genes expressed in spermatogonia.
Topics: Animals; Azacitidine; Decitabine; DNA Methylation; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Neoplasms; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; Spermatogonia; Transcription, Genetic; Tumor Cells, Cultured; X Chromosome | 2003 |
THE CYTOLOGIC AND THE METABOLIC EFFECTS OF A NEW ANTILEUKEMIC ANALOGUE 5-AZACYTIDINE IN NORMAL MICE FOLLOWED AUTORADIOGRAPHICALLY WITH TRITIUM.
Topics: Antineoplastic Agents; Autoradiography; Azacitidine; Bone Marrow Cells; DNA; DNA, Neoplasm; Mice; Neoplasms; Nucleosides; Pharmacology; Research; RNA; RNA, Neoplasm; Thymidine; Tritium | 1965 |
Demethylation of the human telomerase catalytic subunit (hTERT) gene promoter reduced hTERT expression and telomerase activity and shortened telomeres.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cell Division; Cellular Senescence; Decitabine; DNA Methylation; DNA-Binding Proteins; Down-Regulation; Gene Expression Regulation, Neoplastic; Humans; Neoplasms; Promoter Regions, Genetic; Proto-Oncogene Proteins c-myc; RNA, Messenger; Telomerase; Telomere; Transcription, Genetic; Tumor Cells, Cultured | 2003 |
Differential expression of bikunin (HAI-2/PB), a proposed mediator of glioma invasion, by demethylation treatment.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cell Transformation, Neoplastic; DNA Methylation; Female; Gene Expression Regulation, Neoplastic; Glioma; Humans; Male; Membrane Glycoproteins; Methyltransferases; Neoplasm Invasiveness; Neoplasms; Oligonucleotide Array Sequence Analysis; Serine Proteinase Inhibitors; Trypsin Inhibitor, Kunitz Soybean; Tumor Cells, Cultured | 2003 |
Comment on "Chromosomal instability and tumors promoted by DNA hypomethylation" and "Induction of tumors in nice by genomic hypomethylation".
Topics: Animals; Azacitidine; Chromosomal Instability; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Genes, APC; Humans; Incidence; Intestinal Neoplasms; Mice; Neoplasms; Point Mutation; Time Factors | 2003 |
Expression of the p16INK4a gene and methylation pattern of CpG sites in the promoter region in rat tumor cell lines.
Topics: Adenocarcinoma; Animals; Azacitidine; CpG Islands; Cyclin-Dependent Kinase Inhibitor p16; Decitabine; DNA Methylation; Fibroblasts; Gene Silencing; Histiocytoma, Benign Fibrous; Lung Neoplasms; Neoplasms; Osteosarcoma; Promoter Regions, Genetic; Rats; RNA, Messenger; Sulfites; TATA Box; Tumor Cells, Cultured | 2004 |
Cancer chemotherapy targeted at reactivating the expression of epigenetically inactivated genes.
Topics: Antineoplastic Agents; Azacitidine; Clinical Trials as Topic; Decitabine; DNA Methylation; DNA, Viral; Enzyme Inhibitors; Gene Expression; Gene Silencing; Gene Targeting; Herpesvirus 4, Human; Humans; Neoplasms; Promoter Regions, Genetic | 2004 |
Hypermethylation and silencing of the putative tumor suppressor Tazarotene-induced gene 1 in human cancers.
Topics: Antineoplastic Agents; Azacitidine; Cell Division; Cell Line, Tumor; Decitabine; DNA Methylation; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Gene Silencing; Genes, Tumor Suppressor; Humans; Membrane Proteins; Neoplasms; Promoter Regions, Genetic; Protein Biosynthesis; Proteins; Receptors, Retinoic Acid; Tretinoin | 2004 |
Downregulation of 14-3-3sigma in ovary, prostate and endometrial carcinomas is associated with CpG island methylation.
Topics: 14-3-3 Proteins; Azacitidine; Biomarkers, Tumor; Cell Line, Tumor; CpG Islands; DNA Methylation; Down-Regulation; Endometrial Neoplasms; Exonucleases; Exoribonucleases; Female; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Male; Mutation; Neoplasm Proteins; Neoplasms; Ovarian Neoplasms; Prostatic Neoplasms; RNA, Messenger; Tissue Array Analysis; Tumor Suppressor Protein p53 | 2005 |
Aberrant methylation of HIN-1 (high in normal-1) is a frequent event in many human malignancies.
Topics: Adult; Azacitidine; Child; Cytokines; Decitabine; DNA Methylation; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Male; Neoplasms; Promoter Regions, Genetic; RNA, Messenger; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2005 |
Distinct effects on gene expression of chemical and genetic manipulation of the cancer epigenome revealed by a multimodality approach.
Topics: Algorithms; Apoptosis; Azacitidine; Cell Division; Cell Line, Tumor; Cluster Analysis; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3B; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Gene Silencing; Genome; Humans; Hydroxamic Acids; Metallothionein; Methyltransferases; Neoplasms; Oligonucleotide Array Sequence Analysis; Promoter Regions, Genetic; Reproducibility of Results; RNA, Messenger; Transcriptional Activation | 2004 |
Silencing the critics: new studies move closer to answering epigenetic questions.
Topics: Acetylation; Adaptor Proteins, Signal Transducing; Animals; Antimetabolites, Antineoplastic; Azacitidine; Carrier Proteins; Decitabine; DNA Methylation; DNA, Neoplasm; Enzyme Inhibitors; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Histones; Humans; Mutation; MutL Protein Homolog 1; Neoplasm Proteins; Neoplasms; Nuclear Proteins; Phenotype | 2004 |
Epigenetic inactivation of ID4 in colorectal carcinomas correlates with poor differentiation and unfavorable prognosis.
Topics: Adult; Aged; Aged, 80 and over; Azacitidine; Carcinoma; Cell Differentiation; Cell Line, Tumor; Colon; Colorectal Neoplasms; Disease Progression; DNA Methylation; DNA Primers; DNA-Binding Proteins; Female; Humans; Immunohistochemistry; Inhibitor of Differentiation Protein 2; Male; Middle Aged; Models, Genetic; Neoplasms; Polymerase Chain Reaction; Prognosis; Repressor Proteins; Risk; RNA, Messenger; Sequence Analysis, DNA; Sulfites; Time Factors; Transcription Factors | 2004 |
The controversial denouement of vertebrate DNA methylation research.
Topics: Animals; Azacitidine; Decitabine; DNA Methylation; DNA Modification Methylases; Dosage Compensation, Genetic; Gene Expression Regulation, Developmental; Genomic Imprinting; Neoplasms; Vertebrates | 2005 |
Introduction: emerging role of epigenetic therapy: focus on decitabine.
Topics: Azacitidine; Decitabine; DNA Modification Methylases; Epigenesis, Genetic; Humans; Neoplasms; Treatment Outcome | 2005 |
GADD45 deregulation in cancer: frequently methylated tumor suppressors and potential therapeutic targets.
Topics: Amino Acid Sequence; Antimetabolites, Antineoplastic; Azacitidine; Cell Cycle Proteins; Cell Line; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; DNA Modification Methylases; Gene Expression Regulation, Neoplastic; Humans; Models, Biological; Molecular Sequence Data; Neoplasms; Nuclear Proteins; Prognosis; Promoter Regions, Genetic; Sequence Homology, Amino Acid; Tumor Suppressor Proteins | 2005 |
The stress-responsive gene GADD45G is a functional tumor suppressor, with its response to environmental stresses frequently disrupted epigenetically in multiple tumors.
Topics: Antigens, Differentiation; Antimetabolites, Antineoplastic; Azacitidine; Base Sequence; Cell Cycle Proteins; Cell Line; Cell Line, Tumor; Cell Proliferation; CpG Islands; Decitabine; DNA Methylation; DNA Modification Methylases; Gene Expression Regulation, Neoplastic; HeLa Cells; HL-60 Cells; Hot Temperature; HT29 Cells; Humans; Intracellular Signaling Peptides and Proteins; K562 Cells; Mutation; Neoplasms; Nuclear Proteins; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; Tumor Suppressor Proteins | 2005 |
Activator protein 2alpha status determines the chemosensitivity of cancer cells: implications in cancer chemotherapy.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Breast Neoplasms; Cell Line, Tumor; Decitabine; DNA Methylation; Gene Silencing; Humans; Mice; Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Transcription Factor AP-2 | 2005 |
De novo induction of a cancer/testis antigen by 5-aza-2'-deoxycytidine augments adoptive immunotherapy in a murine tumor model.
Topics: Animals; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Azacitidine; Chromatin; CpG Islands; Decitabine; DNA Methylation; Gene Expression Profiling; Humans; Immunotherapy, Adoptive; Lung Neoplasms; Mammary Neoplasms, Animal; Mice; Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Transplantation, Heterologous; Tumor Cells, Cultured | 2006 |
Accurate quantification of DNA methylation using combined bisulfite restriction analysis coupled with the Agilent 2100 Bioanalyzer platform.
Topics: Azacitidine; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; DNA Restriction Enzymes; Electrophoresis, Microchip; Humans; Molecular Diagnostic Techniques; Neoplasms; Polymerase Chain Reaction; Reproducibility of Results; Sulfites | 2006 |
Epigenetic inactivation of Betaig-h3 gene in human cancer cells.
Topics: Azacitidine; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; Epigenesis, Genetic; Extracellular Matrix Proteins; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Genes, Reporter; Humans; Luciferases; Lung Neoplasms; Male; Neoplasms; Promoter Regions, Genetic; Prostatic Neoplasms; Transforming Growth Factor beta | 2006 |
Promoter demethylation and histone acetylation mediate gene expression of MAGE-A1, -A2, -A3, and -A12 in human cancer cells.
Topics: Acetylation; Antigens, Neoplasm; Azacitidine; Blotting, Western; Cell Line, Tumor; Corynebacterium; Decitabine; DNA Methylation; DNA Modification Methylases; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Histone Deacetylases; Histones; Humans; Hydroxamic Acids; Melanoma-Specific Antigens; Neoplasm Proteins; Neoplasms; Promoter Regions, Genetic | 2006 |
DNA mismatch repair as an effector for promoting phorbol ester-induced apoptotic DNA damage and cell killing: implications in tumor promotion.
Topics: Apoptosis; Azacitidine; Base Pair Mismatch; Cell Line, Tumor; CpG Islands; Decitabine; DNA; DNA Damage; DNA Repair; DNA-Binding Proteins; Humans; Methylation; Neoplasms; Phorbol Esters; Protein Kinase C; Protein Kinase Inhibitors; Reactive Oxygen Species | 2006 |
The epigenetic basis for the aberrant expression of kallikreins in human cancers.
Topics: Azacitidine; Breast Neoplasms; Cell Line, Tumor; CpG Islands; Decitabine; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; Humans; Kallikreins; Male; Neoplasms; Ovarian Neoplasms; Prostatic Neoplasms | 2006 |
An EBF3-mediated transcriptional program that induces cell cycle arrest and apoptosis.
Topics: Apoptosis; Azacitidine; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Chromosomes, Human, Pair 10; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Decitabine; DNA Methylation; Epigenesis, Genetic; Female; Gene Deletion; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; Hydroxamic Acids; Intracellular Signaling Peptides and Proteins; Male; Microtubule-Associated Proteins; Neoplasm Proteins; Neoplasms; Promoter Regions, Genetic; Recombinant Fusion Proteins; Transcription, Genetic | 2006 |
Epigenetic cancer therapy makes headway.
Topics: Acetylation; Animals; Antineoplastic Agents; Azacitidine; Decitabine; DNA Methylation; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Histone Deacetylases; Humans; Hydroxamic Acids; Methyltransferases; Neoplasms; Randomized Controlled Trials as Topic; Valproic Acid; Vorinostat | 2006 |
Inhibition of histone deacetylation does not block resilencing of p16 after 5-aza-2'-deoxycytidine treatment.
Topics: Acetylation; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Cycle; Cell Line, Tumor; Chromatin; Cyclin-Dependent Kinase Inhibitor p16; Cyclin-Dependent Kinase Inhibitor p21; Decitabine; DNA Methylation; Dose-Response Relationship, Drug; Fibroblasts; Histone Deacetylase Inhibitors; Histones; Humans; Neoplasms; Phenylbutyrates | 2007 |
Differential promoter methylation may be a key molecular mechanism in regulating BubR1 expression in cancer cells.
Topics: Azacitidine; Base Sequence; Cell Line, Tumor; DNA Methylation; DNA Mutational Analysis; DNA-Binding Proteins; Gene Expression Regulation, Neoplastic; HeLa Cells; Histone Deacetylase 1; Histone Deacetylases; Humans; Jurkat Cells; Molecular Sequence Data; Neoplasms; Polymorphism, Genetic; Promoter Regions, Genetic; Protein Binding; Protein Kinases; Protein Serine-Threonine Kinases; Transcription, Genetic | 2007 |
Epigenetic regulation (DNA methylation, histone modifications) of the 11p15 mucin genes (MUC2, MUC5AC, MUC5B, MUC6) in epithelial cancer cells.
Topics: Acylation; Azacitidine; Chromosomes, Human, Pair 11; Decitabine; DNA Methylation; Epigenesis, Genetic; Epithelial Cells; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Molecular Sequence Data; Mucin 5AC; Mucin-2; Mucin-5B; Mucin-6; Mucins; Neoplasms; Tumor Cells, Cultured | 2007 |
Novel approach for detecting global epigenetic alterations associated with tumor cell aneuploidy.
Topics: Aneuploidy; Azacitidine; Cell Line, Tumor; Cell Separation; Chromosome Aberrations; CpG Islands; Cytogenetics; Diploidy; DNA Methylation; DNA Mutational Analysis; DNA-Binding Proteins; DNA, Neoplasm; HCT116 Cells; HT29 Cells; Humans; Loss of Heterozygosity; Mutation; Neoplasms; Polymerase Chain Reaction; Polymorphism, Genetic; Polymorphism, Restriction Fragment Length; Reproducibility of Results; Transcription Factors; Zinc Fingers | 2007 |
Combining epigenetic and cytotoxic therapy in the treatment of solid tumors.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Clinical Trials as Topic; CpG Islands; Decitabine; DNA Methylation; Drug Resistance, Neoplasm; Epigenesis, Genetic; Humans; Mice; Models, Genetic; Neoplasms | 2007 |
DNA methylation inhibitor 5-Aza-2'-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B.
Topics: Ataxia Telangiectasia Mutated Proteins; Azacitidine; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Checkpoint Kinase 1; Decitabine; DNA; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Damage; DNA Methylation; DNA Methyltransferase 3B; DNA-Binding Proteins; Enzyme Inhibitors; Genetic Markers; Genome, Human; Histones; Humans; Neoplasms; Protein Binding; Protein Kinases; Protein Serine-Threonine Kinases; Tumor Suppressor Proteins | 2008 |
Differential epigenetic regulation of Aiolos expression in human tumoral cell lines and primary cells.
Topics: Acetylation; Antineoplastic Agents; Azacitidine; Cell Culture Techniques; Cell Line, Tumor; Chromatin; CpG Islands; Decitabine; DNA Methylation; Drug Combinations; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Histone Acetyltransferases; Histones; Humans; Hydroxamic Acids; Ikaros Transcription Factor; Jurkat Cells; Neoplasms; Promoter Regions, Genetic; Transcription Factors; Transcriptional Activation; U937 Cells | 2008 |
DNMT1 as a molecular target in a multimodality-resistant phenotype in tumor cells.
Topics: Animals; Antineoplastic Agents; Azacitidine; Cell Line, Tumor; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methyltransferase 3B; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; Hydrogen Peroxide; Neoplasms; Oxidative Stress; Phenotype; Proto-Oncogene Proteins c-fos; Rats | 2008 |
Drug resistance in cancer.
Topics: Alkylating Agents; Antibiotics, Antineoplastic; Antineoplastic Agents; Azacitidine; Cisplatin; Cytarabine; Drug Resistance; Fluorouracil; Humans; Methotrexate; Neoplasms | 1984 |
Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2'-deoxycytidine.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Azacitidine; Base Sequence; Cell Line; Cytotoxicity, Immunologic; Decitabine; DNA Primers; Female; Gene Expression Regulation, Neoplastic; Glyceraldehyde-3-Phosphate Dehydrogenases; Humans; Lymphocytes; Lymphocytes, Tumor-Infiltrating; Melanocytes; Melanoma; Melanoma-Specific Antigens; Molecular Sequence Data; Neoplasm Metastasis; Neoplasm Proteins; Neoplasms; Polymerase Chain Reaction; RNA, Neoplasm; Tumor Cells, Cultured | 1994 |
5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers.
Topics: 5-Methylcytosine; Alleles; Azacitidine; Base Sequence; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Carrier Proteins; Chromosomes, Human, Pair 9; CpG Islands; Cyclin-Dependent Kinase Inhibitor p16; Cytosine; Decitabine; DNA, Neoplasm; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Glioma; Head and Neck Neoplasms; Humans; Lung Neoplasms; Methylation; Molecular Sequence Data; Neoplasm Proteins; Neoplasms; Sequence Deletion; Transcription, Genetic; Tumor Cells, Cultured | 1995 |
The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Azacitidine; Base Sequence; Decitabine; Dinucleoside Phosphates; DNA; DNA Modification Methylases; DNA Primers; DNA Probes; DNA, Neoplasm; Enzyme Inhibitors; Genome, Human; Humans; Male; Melanoma; Melanoma-Specific Antigens; Methylation; Molecular Sequence Data; Neoplasm Proteins; Neoplasms; Polymerase Chain Reaction; Promoter Regions, Genetic; RNA, Messenger; T-Lymphocytes, Cytotoxic; Transcription, Genetic; Tumor Cells, Cultured | 1996 |
Inhibition of DNA methylation by 5-aza-2'-deoxycytidine suppresses the growth of human tumor cell lines.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Cell Division; Cyclin-Dependent Kinase Inhibitor p16; Decitabine; DNA Methylation; DNA Modification Methylases; G1 Phase; Gene Expression; Humans; Mice; Mice, Nude; Neoplasms; Rats; Rats, Nude; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 1998 |
Two members of the human MAGEB gene family located in Xp21.3 are expressed in tumors of various histological origins.
Topics: Alternative Splicing; Amino Acid Sequence; Azacitidine; Base Sequence; Decitabine; DNA, Complementary; Exons; Gene Expression; Humans; Molecular Sequence Data; Neoplasm Proteins; Neoplasms; Sequence Homology, Amino Acid; Sequence Homology, Nucleic Acid; Tumor Cells, Cultured; X Chromosome | 1997 |
The role of epigenetics in cancer. DNA Methylation, Imprinting and the Epigenetics of Cancer--an American Association for Cancer Research Special Conference. Las Croabas, Puerto Rico, 12-16 1997 December.
Topics: Azacitidine; Decitabine; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Genomic Imprinting; Humans; Neoplasms; Societies, Scientific; United States | 1998 |
Biallelic inactivation of hMLH1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers.
Topics: Adaptor Proteins, Signal Transducing; Alleles; Azacitidine; Base Sequence; Carrier Proteins; DNA Methylation; DNA Primers; Humans; Microsatellite Repeats; MutL Protein Homolog 1; Neoplasm Proteins; Neoplasms; Nuclear Proteins; Promoter Regions, Genetic | 1998 |
Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer.
Topics: Adaptor Proteins, Signal Transducing; Azacitidine; Carrier Proteins; Cell Cycle Proteins; CpG Islands; Cyclin-Dependent Kinase Inhibitor p15; Cyclin-Dependent Kinase Inhibitor p16; Decitabine; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; MutL Protein Homolog 1; Neoplasm Proteins; Neoplasms; Nuclear Proteins; Promoter Regions, Genetic; Tissue Inhibitor of Metalloproteinase-3; Transcriptional Activation; Tumor Cells, Cultured; Tumor Suppressor Proteins | 1999 |
Characterization of the GAGE genes that are expressed in various human cancers and in normal testis.
Topics: Amino Acid Sequence; Animals; Antigens, Neoplasm; Azacitidine; Base Sequence; Chromosome Mapping; Cloning, Molecular; COS Cells; Decitabine; Exons; Gene Expression Regulation, Neoplastic; Gene Library; Humans; Male; Melanoma; Molecular Sequence Data; Multigene Family; Neoplasm Proteins; Neoplasms; Recombinant Proteins; Sequence Alignment; Sequence Homology, Amino Acid; Sequence Homology, Nucleic Acid; Testis; Transcriptional Activation; Transfection; Tumor Cells, Cultured; X Chromosome | 1999 |
Unbalanced expression of HLA-A and -B antigens: a specific feature of cutaneous melanoma and other non-hemopoietic malignancies reverted by IFN-gamma.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Azacitidine; Base Sequence; Cells, Cultured; Decitabine; DNA, Complementary; Down-Regulation; Flow Cytometry; HLA-A Antigens; HLA-B Antigens; Humans; Interferon-gamma; Leukocytes, Mononuclear; Melanoma; Molecular Sequence Data; Neoplasms; Phenotype; Recombinant Proteins; Ribonucleases; RNA, Messenger; Sequence Homology, Nucleic Acid; Skin Neoplasms; Tumor Cells, Cultured; Up-Regulation | 2001 |
Hypermethylation in human cancers of the RIZ1 tumor suppressor gene, a member of a histone/protein methyltransferase superfamily.
Topics: Animals; Azacitidine; Base Sequence; Cloning, Molecular; CpG Islands; Decitabine; DNA Methylation; DNA-Binding Proteins; DNA, Neoplasm; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Gene Silencing; Genes, Tumor Suppressor; Histone Methyltransferases; Histone-Lysine N-Methyltransferase; Humans; Methyltransferases; Molecular Sequence Data; Neoplasms; Nuclear Proteins; Promoter Regions, Genetic; Protein Methyltransferases; Rats; Retinoblastoma Protein; RNA, Messenger; Transcription Factors; Zinc Fingers | 2001 |
MRNA expression of genes altered by 5-azacytidine treatment in cancer cell lines is associated with clinicopathological parameters of human cancers.
Topics: Actin Depolymerizing Factors; Adult; Aged; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Azacitidine; Cell Adhesion Molecules; DNA Methylation; Epithelial Cell Adhesion Molecule; Female; Gene Expression Regulation, Enzymologic; Genes, BRCA2; Humans; Male; Microfilament Proteins; Middle Aged; Neoplasm Proteins; Neoplasms; Nuclear Proteins; Phosphoprotein Phosphatases; Protein Phosphatase 2C; RNA, Messenger; Transcription Factors; Tumor Cells, Cultured | 2001 |
The clinical pharmacology of antineoplastic agents (second of two parts).
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Azacitidine; Bleomycin; Carmustine; Cell Nucleus; Chemical Phenomena; Chemistry; Cyclohexanes; Cyclophosphamide; Cytarabine; DNA, Neoplasm; Doxorubicin; Humans; Neoplasms; Nitrosourea Compounds | 1975 |
Carcinoembryonic antigen (CEA) monitoring in the management of radiotherapeutic and chemotherapeutic patients.
Topics: Antigens, Neoplasm; Azacitidine; Carcinoembryonic Antigen; Dacarbazine; Fluorouracil; Humans; Monitoring, Physiologic; Neoplasms; Radioisotope Teletherapy | 1975 |
Uridine kinase activities in normal and neoplastic lymphoid cells.
Topics: Animals; Azacitidine; B-Lymphocytes; Carcinoma, Hepatocellular; Cats; Enzyme Induction; Humans; Isoenzymes; Leukemia, Experimental; Leukemia, Lymphoid; Liver Neoplasms; Lymphocyte Activation; Lymphocytes; Lymphoma, Non-Hodgkin; Male; Mast-Cell Sarcoma; Mice; Middle Aged; Neoplasms; Neoplasms, Experimental; Phosphotransferases; Rats; T-Lymphocytes; Uridine Kinase | 1977 |
Clinical pharmacology of anticancer drugs.
Topics: Animals; Antineoplastic Agents; Azacitidine; Bleomycin; Cyclophosphamide; Cytarabine; Dacarbazine; Daunorubicin; Doxorubicin; Female; Fluorouracil; Heart; Humans; Leucovorin; Lung; Male; Methotrexate; Neoplasms; Nitrosourea Compounds; Procarbazine; Triazenes; Vinblastine; Vincristine | 1977 |
A phase I and pharmacokinetic study of dihydro-5-azacytidine (NSC 264880).
Topics: Adult; Aged; Azacitidine; Drug Evaluation; Drug Stability; Female; Humans; Kinetics; Male; Middle Aged; Neoplasms | 1985 |
Induction of adipocyte formation in 10T1/2 cells by 1-methylguanine and 7-methylguanine.
Topics: Adipose Tissue; Animals; Azacitidine; Cell Differentiation; DNA; Guanine; Methylation; Mice; Neoplasms | 1985 |
3-Deazauridine (NSC 126849): an interesting modulator of biochemical response.
Topics: 3-Deazauridine; Acute Disease; Animals; Antineoplastic Agents; Azacitidine; Cytarabine; Decitabine; Drug Evaluation; Drug Synergism; Galactosamine; Humans; Kinetics; Leukemia; Neoplasms; Thymidine; Uridine | 1986 |
On the possible contribution of DNA hypomethylation to the induction of high frequency and heritable drug-induced alterations in the malignant phenotype.
Topics: Alkylating Agents; Animals; Azacitidine; Cell Line; DNA, Neoplasm; Gene Amplification; Humans; Methylation; Mice; Mutagens; Mutation; Neoplasms; Neoplasms, Experimental; Phenotype; Thymidine Kinase | 1986 |
Phase I and pharmacokinetic study of 5-aza-2'-deoxycytidine (NSC 127716) in cancer patients.
Topics: Adult; Aged; Azacitidine; Creatine; Decitabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Evaluation; Female; Humans; Kinetics; Leukocyte Count; Male; Metabolic Clearance Rate; Middle Aged; Neoplasm Recurrence, Local; Neoplasms; Platelet Count; Temperature; Time Factors | 1986 |
Phase I trial and pharmacokinetic evaluation of fazarabine in children.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Child; Drug Evaluation; Female; Humans; Infusions, Intravenous; Male; Metabolic Clearance Rate; Neoplasms | 1989 |
Arabinofuranosyl-5-azacytosine: activity against human tumors in athymic mice.
Topics: Animals; Antineoplastic Agents; Azacitidine; Cell Transformation, Neoplastic; Cytarabine; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Female; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms; Stereoisomerism; Time Factors; Transplantation, Heterologous; Tumor Cells, Cultured | 1989 |
Hepatotoxicity of 5-azacytidine (NSC-102816) (a clinical and pathologic study).
Topics: Acute Disease; Adult; Aged; Azacitidine; Chemical and Drug Induced Liver Injury; Cytidine; Female; Humans; Kupffer Cells; Liver; Male; Middle Aged; Neoplasms; Triazines | 1973 |
[New cytostatics in oncological therapy].
Topics: Antineoplastic Agents; Azacitidine; Breast Neoplasms; Chemical Phenomena; Chemistry; DNA Replication; DNA, Neoplasm; Doxorubicin; Drug Therapy, Combination; Humans; Leukemia, Lymphoid; Lymphoma; Male; Mitolactol; Neoplasms; Nitrosourea Compounds; Testicular Neoplasms; Thyroid Neoplasms | 1974 |
Biological effects of 5-azacytidine in eukaryotes.
Topics: Animals; Azacitidine; DNA; DNA, Bacterial; DNA, Viral; Drug Resistance; Embryo, Mammalian; Enzyme Induction; Gastric Juice; Humans; Leukemia, Lymphoid; Liver; Liver Regeneration; Neoplasms; Neoplasms, Experimental; Polyamines; Polyribosomes; Protein Biosynthesis; RNA; Spleen; Tyrosine Transaminase; Uridine Kinase | 1974 |